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ABSTRACT
INVESTIGATION OF INFLUENZA B VIRUS REPLICATION POTENTIAL IN
SWINE PRIMARY RESPIRATORY EPITHELIAL CELLS AND PHYLODYNAMIC
ANALYSIS OF EQUINE INFLUENZA A H3N8 VIRUSES
SUNAYANA SHYAM JANDHYALA
2019

Influenza viruses are respiratory pathogens that cause significant mortality worldwide.
The subtype of influenza A virus currently affecting worldwide equine populations is
H3N8, leading to epidemics and transboundary pandemics. The individual gene segments
of an isolate named A/equine/Montana/9564-1/2015 were phylogenetically characterized.
BLASTn search revealed that the polymerase basic protein 1 (PB1), polymerase acidic
(PA), hemagglutinin (HA), nucleoprotein (NP), and matrix (M) segments of this H3N8
isolate shared the highest percentage identity to A/equine/Tennessee/29A/2014 (H3N8)
and the polymerase basic protein 2 (PB2), neuraminidase (NA), and non-structural
protein (NS) segments to A/equine/Malaysia/M201/2015 (H3N8). Maximum likelihood
phylogenetic trees constructed using H3N8 viral genomes of both equine and canine
origin, established that A/equine/Montana/9564-1/2015 belonged to the Florida Clade 1
viruses.
A review of the current progress in influenza B virus (IBV) research includes the peerreviewed articles that have been published on five IBV proteins. Understanding the
biology of the proteins encoded in the IBV genome, and their differences from IAV, is
crucial in for vaccine research. The current understanding of the evolutionary dynamics
and epidemiology of IBV is discussed which helps inform vaccine strategies and prevent

xi
IBV infections. Although IBV is thought to primarily infect humans, there is evidence of
sporadic infections occurring in other species. These studies of natural and experimental
infections of IBV are discussed, followed by a summary of the current literature on the
studies done in ferrets.
Swine are susceptible to infection by IBV, indicating that IBV could be a swine pathogen
and natural reservoir for IBV. The second study looked at the replication kinetics of
Victoria and Yamagata lineages of IBV in swine primary nasal turbinate, trachea and
lung epithelial cells. Productive replication of B/Brisbane/60/2008 (BR08);
B/Florida/04/06 (FL06); B/Hong Kong/286/2017 (HK17) and B/Utah/09/2014 (UT14)
was seen at 0.01 and 0.1 multiplicities of infection. Peak titers at 33˚C were greater than
or equal to titers at 37˚C for most of the experiments. HK17 (Victoria lineage) grew to
the highest titers in nasal turbinate and lung cells. Lineage-specific differences in
replication could not be observed in this study. Molecular analysis of will shed more light
on the role of swine in the pathogenesis of IBV.
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Chapter 1 Introduction and Objectives
1.1 Classification of Influenza Viruses
Influenza viruses belong to the family Orthomyxoviridae. Viruses that are a part of the
Orthomyxoviridae family contain virions that are spherical or pleomorphic in shape.
Influenza virions measure approximately 80-120 nm in diameter. They are enveloped
viruses that contain a segmented negative sense RNA genome. Having diversified
through evolution, influenza viruses are classified into types A, B and C. This
classification is based on the antigenic differences in nucleocapsid (NP) and matrix (M1)
proteins.
Influenza A (IAV) and B (IBV) viruses are predominantly responsible for annual
influenza in humans. Characterized by symptoms such as cough, fever, muscle and joint
pain, sore throat and a runny nose, influenza is estimated to be responsible for 290,000 to
650, 000 global deaths annually. This respiratory disease can spread rapidly, impacting
children (less than 59 months old) and the elderly (older than 65 years of age) to a greater
degree (W. Paul Glezen et al., 1980; Van Voris, Belshe, & Shaffer, 1982). Both IAV and
IBV are included in the seasonal flu vaccine for humans.
IAV is divided into subtypes based on the hemagglutinin (HA) and the neuraminidase
(NA) proteins. 18 different HA subtypes and 11 different NA subtypes have been
discovered. Isolated for the first time in 1940, Influenza B virus comprises of a single
group of HA and NA antigens (Francis, 1940; Nerome et al., 1998). Unlike IAV which
has been isolated from several wild and domestic animals such as swine, equine, seals,
whales, mink and birds. IBV has been primarily associated with human infections
(Cauldwell, Long, Moncorge, & Barclay, 2014). Despite humans being considered the
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predominant host, there is evidence to show that other species such as pheasants, horses,
dogs and seals can harbor IBV or possess antibodies specific to IBV (Bodewes et al.,
2013; Chang CP, 1976; Kawano J, 1978).
Unlike IAV and IBV which have eight genome segments, Influenza C virus (ICV) has
seven genome segments. The Hemagglutinin Esterase Fusion (HEF) protein is the only
glycoprotein present at the surface of the ICV virion. It combines the receptor binding
activity (mediated by HA in IAV and IBV), receptor destroying activity (mediated by NA
in IAV and IBV) and fusion activity in ICV (Georg Herrler & Klenk, 1991). There are
reports of ICVs in pigs, feral dogs and dromedary camels, but ICV is primarily known to
cause a mild respiratory disease in humans (Guo, Jin, Wang, Wang, & Zhu, 1983;
Ohwada et al., 1987).
Influenza D virus (IDV) was discovered in 2011 in a pig that showed influenza-like
symptoms in Oklahoma. IDV shares approximately 50% homology to ICV, but
differences in the receptor binding pocket of HE protein have modelled (Hause et al.,
2013). While IDV’s prevalence is highest in cattle with this agricultural animal as a
primary reservoir, antibodies to IDV have been found in pigs, goats and sheep (Quast et
al., 2015). Not much is known about the potential zoonotic transmission of IDV to
humans, but increased transmission in animal reservoirs indicates that IDV may pose a
public health concern (Hause et al., 2013).
Influenza viruses have a wide host range, with some animal species being susceptible to
infection by all four types of viruses. The segmented nature of influenza viruses enables
reassortment when cells are infected simultaneously with different human and animal
viruses. This is known as antigenic shift. Antigenic shift, which occurs in IAV can create
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novel viruses to which humans are susceptible as they have no preexisting immunity. For
example, the Hong Kong flu of 1968 which was caused by an antigenic shift of H2N2
strain to H3N2 strain, caused the death of approximately one million people worldwide.
Antigenic drift is the accumulation of mutations in genes of influenza viruses that code
for antibody-binding sites. These mutations allow the virus to escape preexisting
immunity and cause widespread mortality. The outbreaks due to antigenic drifts are
usually less severe than the pandemics associated with antigenic shifts. These periodic
changes in the antigenic properties of influenza viruses cause its epidemic nature. Thus,
an understanding of the biology, epidemiology and transmission of influenza viruses in
various species will aid in the development of antiviral therapies to fight infections.
1.2 Structure and Genome Organization of Influenza Viruses
The influenza virion contains helical ribonucleoprotein complexes (also called vRNPs).
vRNPs are a central part of the viral life cycle. The virion has a viral envelope that
contains a core. Three transmembrane proteins are a part of the viral envelope: HA
(Hemagglutinin), NA (Neuraminidase) and M2 (Ion channel) are present on the outside;
M1 (matrix protein) is present beneath the membrane. HA is the major protein forming
the viral envelope. It contains binding sites for neutralizing antibodies as well as the sialic
acid receptor. Cleavage of HA into HA1 and HA2 is essential for virus infection. NA,
which forms tetrameric spikes, is responsible for removing the sialic acid receptor
enabling release of infectious viral particles which causes spread of the infection. M2, the
minor component of the viral envelope, functions as an ion channel. When influenza
viruses are budding from infected cells, the outer lipid layer is taken from the host’s
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plasma membrane. M2 protein is instrumental in the release and exit of the vRNPs from
the M1 matrix (Nayak, Balogun, Yamada, Zhou, & Barman, 2009).
The viral core has vRNPs that contain negative stranded vRNAs and nucleoprotein (NP).
Nuclear export protein (NEP) is present in small amounts along with the three
polymerase proteins named PB1, PB2 and PA. This forms the viral RNA polymerase
complex (Wu & Voth, 2003).
IAVs encode 10 polypeptides that are derived from 8 viral RNA segments (Figure 1.1).
In IAV and IBV, segments 1, 3, 4 and 5 encode one protein per segment: PB2, PA, HA
and NP proteins. Polymerase subunit 1 (PB1) is encoded on segment 2 in all influenza
viruses. Some strains of IAV also have a PB1-F2 protein which contains 87 amino acids,
in a +1 alternate reading frame. PB1- F2 has been implicated in killing host cells (W.
Chen et al., 2001). While segment 6 encodes only the NA protein (Bouvier & Palese,
2008) in IAV, in IBV it encodes the NB protein too in a -1 reading frame. NB protein
corresponds to the M2 protein in IAV. IAV expresses the M2 ion channel from segment
7, while IBV encodes its BM2 protein in a +2 alternate reading frame. NS1 interferonantagonist protein is expressed from segment 8 in both IAV and IBV. The NEP/NS2
protein is expressed by mRNA splicing from this segment (Bouvier & Palese, 2008).
ICV is similar in genome organization to IAV and IBV; it consists of only seven
segments as HEF combines the functions of HA and NA. ICV uses Neu5,9Ac2 (N-acetyl9-O-acetylneuraminic acid), while IAV and IBV utilize Neu5Ac (N-acetylneuraminic
acid). While human IAV preferentially binds to α2-6 linkage, avian IAV binds to α2-3
linkage, and swine IAV can binds to both α2-6 and α2-3 linkages. ICV’s HEF recognizes
Neu5,9Ac2 receptor regardless of its linkage to the next sugar. The HEF also has esterase
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activity which cleaves acetyl from the C9 position of sialic acid-containing glycans (G.
Herrler et al., 1985).

Figure 1.1 Diagrammatic illustration of the genome organization of influenza A
virion(Horimoto & Kawaoka, 2005)

1.3 Replication of Influenza Viruses
A diagrammatic illustration of the replication of influenza viruses is shown below (Figure
1.2). The first step of virus replication is the virus entry. The HA protein undergoes
cleavage into HA1 and HA2 by serine proteases. HA1 contains the receptor binding and
antigenic sites, whereas HA2 mediates fusion of the viral envelope with the cell
membrane. Viruses often undergo amino acid changes at antigenic sites, and these minor
changes can accumulate in a process known as antigenic drift. After the virus is
endocytosed, a low pH environment in the endosome facilitates a conformational change
in the HA, and the fusion peptide is exposed. The viral envelope is then merged with the
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endosomal membrane through the fusion peptide. After endocytosis, the M2 protein ion
channel causes the flow of ions from the endosome to the interior of the virus. This
causes a disruption in the protein-protein interactions within the cell allowing the release
of the ribonucleoprotein structure from the membrane (M1) protein (Helenius, 1992).
This allows RNPs to be released from the matrix of the virus into the cytoplasm of the
cell.
Viral proteins and RNPs are imported into the nucleus where the influenza viral RNA
synthesis occurs. vRNA is the template to synthesize mRNA templates for viral protein
synthesis. At the same time, vRNA is used as the template to make complementary RNA
(cRNA) intermediates from which the RNA polymerase can transcribe more vRNA. The
poly(A) tail is encoded in a negative sense vRNA, which is then transcribed into the
positive sense mRNA. mRNA capping occurs through a process called “cap snatching”.
PB1 and PB2 proteins are involved in taking 5’ capped primers from pre-mRNA
transcripts of the host cell, to initiate viral mRNA synthesis.
Viral mRNA is then exported and translated into viral proteins in a similar fashion to the
host mRNA. vRNA is exported to the cytosol with the help of M1 and NEP/NS2
proteins. Within the RNA complex, vRNA and NP interact with M1. NEP also interacts
with M1 to mediate the export of the M1-RNP complex via nucleoporins in the
cytoplasm. HA, NA and M2 envelope proteins are synthesized from the mRNA of viral
origin on the ribosomes. They are moved into the endoplasmic reticulum, where folding
occurs. Following folding, the mRNA is trafficked into the Golgi apparatus for posttranslational modifications.
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In the next step, the viral RNA is packaged and assembled. There is evidence that
packaging signals exist on vRNA segments which helps the full genome incorporate into
the viral particles efficiently. After assembly, influenza virus budding occurs. Influenza
HA protein is a driving force for virus to pinch-off from the cell surface of infected cells
with the help of influenza M2 protein. Virus particles are released through the sialidase
activity of NA protein. Through NA’s activity of breaking down mucins in the respiratory
tract, it aids in virus infectivity.

Figure 1.2 Replication of influenza viruses
(Arias et al., 2009)
1.4 Epidemiology and evolution of EIV and IBV
Influenza A viruses infect animals and humans, whereas influenza B viruses mainly
infect humans. Influenza A virus is considered to be the ancestor of all other influenza
viruses. H7N7 and H3N8 are the subtypes that are related to equine influenza. H3N8 is
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the only subtype that currently circulates in equines. Isolated for the first time in 1963,
A/eq/Miami/63 is considered the prototype EIV isolate (Waddell, Teigland, & Sigel,
1963).
The oldest H3N8 EIV isolates, dated from 1963 to 1988, were grouped under the predivergence lineage. Differences in the sequence analysis of the HA gene led to the
classification of EIV into the Eurasian and American lineages. The American lineage
evolved into the Argentinian, Kentucky and Florida sub lineages (Lai et al., 2001). The
Florida sub lineages can be further classified into Clade 1 and Clade 2 viruses. Clade 1
viruses include representative strains such as A/eq/South Africa/04/2003-like and
A/eq/Ohio/2003-like viruses, and has caused outbreaks in Mongolia, India and China.
Clade 2 viruses are representative of strains like A/eq/Richmond/1/2007-like viruses.
Interestingly, some isolates from Europe have changes in their amino acid sequences
which makes them similar to Clade 2 lineages viruses (Bryant et al., 2009).
Studies on the phylogeny of EIV from different parts of the world have demonstrated the
evolution of EIV. Surveillance studies in North America detected the presence of EIV in
Canada and West Indies. A 56.6% morbidity rate of EIV amongst equine respiratory
outbreaks was seen in Ontario, Canada during five different outbreaks (Diaz-Mendez et
al., 2010). EIV antibodies have also been reported from horses and donkeys in the
Leeward Islands of West Indies (Bolfa et al., 2017). A high prevalence of antibodies
against EIV has also been reported in Brazil, with movement and aggregation of animals
possibly causing high rates of transmission (Favaro et al., 2018).
The genetic evolution EIV in France showed that American and Eurasian lineages
prevailed till 2003, but after 2005 the Florida sub lineage Clade 2 was dominant
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(Legrand, Pitel, Cullinane, Fortier, & Pronost, 2015). EIV isolates were detected in
Ireland, Sweden and the UK as well (Back et al., 2016; Gildea, Quinlivan, Arkins, &
Cullinane, 2012). Several of these studies highlight the possibility of reassortment as a
mechanism for EIV evolution.
Asia had EIV infections in several countries such as China, Mongolia, India and Japan
(Qi et al., 2010). Amino acid changes in the antigenic sites were seen in Asian strains of
Florida sub lineage clade 2. Differences between the isolates and the vaccine strain were
due to amino acid substitutions in A, B and C antigenic regions (Qi et al., 2010). Thus,
the emergence of newer strains due to mutations is an issue worldwide. The high number
of circulating strains and lack of cross-protection highlights the importance of regular
surveillance and evolutionary profiling of this respiratory disease.
Unlike IAV which is divided into several subtypes based on the antigenicities of
hemagglutinin (HA) and the neuraminidase (NA) proteins, IBV does not have any
subtypes. In the 1980s, IBV diverged into two genetically and antigenically distinct
lineages named Victoria and Yamagata after B/Yamagata/16/88 and B/Victoria/2/87,
which were the original isolates (Rota et al., 1990). The Victoria lineage viruses belong
to the B/Brisbane/60/2008 genetic clade (Group 1), whereas the Yamagata lineage
viruses are classified into two clades. Group 2 in the Yamagata lineage is represented by
B/Brisbane/3/2007, and Group 3 is represented by B/Bangladesh/3333/2007. In seasons
where IBV was predominant or co-circulating alongside influenza A virus (IAV),
Victoria lineage predominated 64% of seasons, whereas Yamagata lineage predominated
36% of seasons (Caini et al., 2015)
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Victoria-like viruses were prevalent worldwide in the 1980s, but the Yamagata emerged
worldwide in the 1990s. In some parts of Asia, Victoria-like viruses circulated in the late
1990s, but this lineage re-emerged globally in 2001. Phylogenetic trees constructed from
the HA genes showed that the Victoria lineage comprised of a single tree-trunk that had
several side branches which circulated for short periods of time indicating that it
undergoes greater positive selection, whereas Yamagata lineage has multiple clades
circulating at the same time (Vijaykrishna et al., 2015). Additionally, Yamagata viruses
bind predominantly to α-2,6-linked sialic acid host receptors whereas Victoria viruses
bind to both α-2,3 and α-2,6 binding capacities.
Molecular analysis of viral genes provides an insight into the epidemic potential of
different strains. Phylogenetic analysis, in particular, enables the identification of
circulating strains belonging to different lineages (Lindstrom et al., 1999; Rota et al.,
1990). performing a molecular analysis of viral genes provides an insight into the
epidemic potential of different strains by allowing the identification of amino acid
residues that contribute to antigenic drift. Phylogenetic analysis also enables the
identification of circulating strains belonging to different lineages (Lindstrom et al.,
1999; Rota et al., 1990).
Epidemiological studies from several European countries like Belgium, Spain, Finland
and Israel highlight the reassortment of circulating strains. Phylogenetic analysis of
circulating strains reveal an evolutionary pattern of IBV that has alternatingly dominant
lineages and their co-circulation during a particular season.

1.5 Objectives
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The aim of the study in chapter 2 was to characterize an equine H3N8 virus isolate. This
isolate was obtained from a 3-year-old unvaccinated horse having respiratory disease,
from Montana, USA, in 2015. Phylogenetically distinct clades/lineages of EIV have been
co-circulating globally, posing a challenge in the selection of vaccine strains.
Understanding the evolutionary profile of EIV helps estimate the phylogenetic diversity
and distribution of equine influenza viruses. Phylogenetic characterization of all the eight
gene segments of this isolate was done using currently available sequences of both canine
and equine H3N8 subtypes in the influenza virus resource database.
Current progress in IBV research is discussed in Chapter 3. Findings on IBV proteins
such as the polymerase proteins, nucleoprotein, non-structural protein 1, matrix protein
and hemagglutinin proteins are discussed in brief. The epidemiology of Victoria and
Yamagata lineages of IBV are discussed, and the evolutionary dynamics of IBV. Nonhuman IBV infections are discussed: both experimental and natural.
The ability of IBV to infect swine primary respiratory epithelial cells derived from the
nasal turbinate, trachea and lung cells of a day-old gnotobiotic piglet was investigated in
chapter 4. The effect of different multiplicities of infection and temperature on IBV
replication was also looked at in this study. The replication of B/Brisbane/60/2008
(BR08) and B/Hong Kong/286/2017 (HK17) belonging to the Victoria lineage, and
B/Florida/04/06 (FL06) and B/Utah/09/2014 (UT14) belonging to the Yamagata lineage
was studied at 33˚C and 37˚C. The three primary cells, and MDCK cells which were used
as a positive control, were infected with the four strains of IBV at 0.01 and 0.1
multiplicities of infection. This study aids in a greater understanding of the pathogenesis
of IBV in swine.
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Chapter 2 Phylogenetic Analysis of a Sporadic Isolate of Equine Influenza A H3N8
from an Unvaccinated Horse in 2015
2.1 Abstract
Equine influenza, caused by the H3N8 subtype, is a highly contagious respiratory disease
affecting equid populations worldwide and has led to serious epidemics and
transboundary pandemics. This study describes the phylogenetic characterization of a
recently isolated H3N8 virus from a nasal swab obtained from a sporadic case of natural
infection in an unvaccinated horse from Montana, USA. BLASTn search revealed that
the polymerase basic protein 1 (PB1), polymerase acidic (PA), hemagglutinin (HA),
nucleoprotein (NP), and matrix (M) segments of this H3N8 isolate shared the highest
percentage identity to A/equine/Tennessee/29A/2014 (H3N8) and the polymerase basic
protein 2 (PB2), neuraminidase (NA), and non-structural protein (NS) segments to
A/equine/Malaysia/M201/2015 (H3N8). Phylogenetic characterization of individual gene
segments, using currently available H3N8 viral genomes, of both equine and canine
origin, further established that A/equine/Montana/9564-1/2015 belonged to the Florida
Clade 1 viruses. This study provided us insights about the evolutionary relationship and
in vitro cross-species infectivity of A/equine /Montana/9564-1/2015 (H3N8) virus.
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2.1 Introduction
Equine influenza epizootics, which affect horses, zebra, mules, and donkeys all over the
world, are characterized by an acute dry cough, high body temperature, mucopurulent
nasal discharge, lethargy and anorexia (Cardwell, Newton, Wood, Geraghty, & Ellis,
2000; Lai et al., 2001; Mumford et al., 1998; Timoney, 1996). Vaccination failure, the
mobility of unvaccinated horses and insufficient quarantine measures are major
predisposing factors for equine influenza occurrence in places where EIV is endemic
(Cullinane & Newton, 2013). Equine influenza viruses are type A viruses and the major
subtypes affecting horses include H7N7 and H3N8 which were previously designated as
equine 1 and equine 2 viruses. However, currently, H3N8 (Kitchen, Kehler, &
Henthorne, 1963) is the only subtype affecting worldwide equine populations.
A1/equine/Prague/56 was the first H7N7 prototype isolated from Prague, Czech
Republic, which affected horses in Sweden and Eastern Europe around 1955–1956
(Scholtens, Steele, Dowdle, Yarbrough, & Robinson, 1964; Sovinova, Tumova, Pouska,
& Nemec, 1958; Webster, 1993). Equine H3N8 prototype, A2-equine/Miami/63 was
originally isolated from Miami, Florida in 1963, as an upper respiratory disease
manifestation in imported animals from Argentina (Kitchen et al., 1963; Waddell et al.,
1963; Wilson, Bryans, & Doll, 1965). Since 1979, only H3N8 variants have been found
in circulation, even though both H7N7 and H3N8 co-circulated in the equine populations
in earlier times (Cullinane & Newton, 2013; Daly et al., 1996; Webster, 1993). It is
believed that homo/intra and hetero/inter-subtype reassortments have played a crucial
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role in the evolution dynamics of equine influenza virus (EIV), where intra-subtype
reassortments enhanced virulence in EIV H3N8, and inter-subtype reassortments led to
the extinction of EIV H7N7 (Murcia, Wood, & Holmes, 2011). Compared to H7N7,
H3N8 affects horses of all ages, irrespective of vaccination coverage. Previous studies on
the phylogeny of EIV from different parts of the world have clearly demonstrated the
evolution of equine influenza viruses, particularly the H3N8 subtype, which is the
prominent subtype in circulation (Alves Beuttemmuller et al., 2016; Bountouri,
Fragkiadaki, Ntafis, Kanellos, & Xylouri, 2011; Fougerolle et al., 2017; Olguin
Perglione, Golemba, Torres, & Barrandeguy, 2016; Perglione et al., 2016; Rash et al.,
2017). EIV H3N8 has been causing major transcontinental pandemics across the world
and has crossed over species to successfully establish in the canine host since 2004
(Crispe, Finlaison, Hurt, & Kirkland, 2011).
The equine H3N8 subtype diverged genetically into American and Eurasian lineages
around the 1980s, however American lineages have been circulating in Europe and viceversa (Bryant et al., 2009; Daly et al., 1996). No cases of Eurasian lineages have been
reported since 1994 (Murcia et al., 2011). Around 1990, the American lineage diverged
antigenically and genetically into Kentucky, South America and Florida sub-lineages
with the Florida sub-lineage circulating predominantly (Lai et al., 2001). Around the
early 2000s, the Florida sub-lineage diverged into two clades: Clade 1 (FC1) and Clade 2
(FC2) (Bryant et al., 2009; Xie, Anderson, Daramragchaa, Chuluunbaatar, & Gray, 2016;
Yamanaka et al., 2016). Even though the clade separation was not so pronounced for the
H3N8 isolates in 2002–2003, the divergence became indisputable for strains isolated after
2005 (Paillot, 2014). Since 2007, all Asian and European isolates have been found to
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belong to FC2, whereas North American isolates belong to FC1, but the reverse can also
occur, owing to the increased international mobility of the animals for races and
exhibition. Such activities can lead to loose transmission bottle-neck and mixed
infections, which may contribute to vaccination failures (Hughes et al., 2012; Murcia et
al., 2011).
Cross-species transmission of EIV in canines, characterized by the complete genome
transfer of equine H3N8, occurred initially in the United States, followed by the UK and
Australia in the early 2000s (Gonzalez et al., 2014; Kirkland, Finlaison, Crispe, & Hurt,
2010). Canine influenza, caused by H3N8, has been associated with fever, cough,
suppurative pneumonia and per-acute death (Crawford et al., 2005; Daly et al., 2008;
Kirkland et al., 2010; Murcia & Wood, 2011). Both cats and calves have been
experimentally infected with EIVs and the infected animals showed clinical symptoms,
virus shedding and demonstrated contact transmission (Lin et al., 2010; Su et al., 2014;
Tu et al., 2009). Interestingly, two H3N8 strains of equine origin, with close relation to
the European H3N8 EIVs, were isolated from pigs in China during 2004–2006 (Tu et al.,
2009). Experimental infection of humans with EIV H3N8 was demonstrated more than
50 years ago by the National Institute of Health and it was found that humans are
susceptible to H3N8 with clinical manifestations (Kasel, Alford, Knight, Waddell, &
Sigel, 1965; Minuse, McQueen, Davenport, & Francis, 1965; Morens & Taubenberger,
2010). Further, serological evidence of EIV H3N8 has been reported in humans with
occupational exposure indicating its zoonotic potential (Larson et al., 2015). These
evidence of cross-species transmission and broad host spectrum raise the possibility of
zoonosis and thus could have a serious implication on public health.
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Previous outbreaks in vaccinated and unvaccinated horses in Europe in 1979 and 1989
showed that EIV can undergo a rapid rate of antigenic drift and cause vaccination failures
(Van Oirschot, Bruin, de Boer-Luytze, & Smolders, 1991; van Oirschot, Masurel,
Huffels, & Anker, 1981). The Office International des Epizooties (OIE) vaccine
recommendations remain unchanged since 2010, and mandates to include both clades—
FC1 represented by A/eq/South Africa/04/2003-like or A/eq/Ohio/2003-like viruses and
FC2 represented by A/eq/Richmond/1/2007-like viruses. The OIE also recommends
periodical update of the vaccine strains, based on the epidemiological survey results
(Paillot et al., 2016). While, vaccination is the only solution to effectively control and
prevent EIV outbreaks, the continuous antigenic drift between the strains poses a serious
threat for necessary protection, especially for horses involved in cross country events
(Elton & Cullinane, 2013). Continued surveillance and reporting of EIV from different
countries is of utmost importance, to ensure the effective coverage of circulating strains
by the current vaccine strains and thereby boosts herd immunity.
The aim of this study was to phylogenetically characterize all eight segments of an equine
H3N8 virus isolate, obtained from a 3-year-old unvaccinated gelding showing respiratory
disease, from Montana, USA, in 2015. Phylogenetically distinct clades/lineages of EIV
have been co-circulating globally, undergoing gene reassortments, thereby posing a
serious challenge in the selection of vaccine strains. Hence, understanding the
evolutionary profile of EIV is imperative to estimate the phylogenetic diversity and
distribution of equine influenza viruses. Our phylogenetic analysis inferred that the
polymerase basic protein 1 (PB1), polymerase acidic (PA), and nucleoprotein (NP)
segments of A/equine/Montana/9564-1/2015 clustered with
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A/equine/Tennessee/29A/2014 and hemagglutinin (HA), polymerase basic protein 2
(PB2), neuraminidase (NA), matrix (M), and non-structural (NS) segments clustered with
A/equine/Malaysia/M201/2015 and A/equine/Tennessee/29A/2014, both belong to Clade
1 (FC1) viruses of Florida sub-lineage (Bao et al., 2008).

2.2 Materials and Methods
A BLASTn search analysis, optimized for highly similar sequences (megablast), was
conducted for all the eight gene segments of A/equine/Montana/9564-1/2015 (H3N8) (Y.
Chen, Ye, Zhang, & Xu, 2015).
Both canine and equine nucleotide sequences of H3N8 subtype were acquired from the
influenza virus resource (https://www.ncbi.nlm.nih.gov/genomes/FLU/Database/nphselect.cgi?go=database, accessed 5 January 2018) and phylogenetic analyses were
performed using MEGA 7.0. Nucleotide sequences were aligned using Multiple
Sequence Comparison by Log-Expectation (MUSCLE) and the evolutionary history of
each segment was inferred by constructing maximum likelihood trees, using the best
nucleotide substitution models, suggested by the ‘test for best DNA/ protein fitness’ in
MEGA 7.0 (Bao et al., 2008; Edgar, 2004). The best nucleotide substitution models
inferred for maximum likelihood trees for the gene segments were general timereversible with gamma distributed with invariant sites (GTR+G+I) for PB2, PB1, NP;
Tamurai–Nei with gamma distributed with invariant sites (TN93+G+I) for PA, HA;
general time-reversible with gamma distributed (GTR+G) for NA; Hasegawa-KishinoYano with gamma distributed with invariant sites (HKY+G+I) for M; Hasegawa–
Kishino–Yano with gamma distributed (HKY+G) for NS (Hasegawa, Kishino, & Yano,
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1985; Rodriguez, Oliver, Marin, & Medina, 1990; Tamura & Nei, 1993). All nucleotide
positions containing gaps and missing data were partially deleted and very strong branch
filters were applied to run the analysis. For each taxon, the bootstrap value was
determined from 1000 replicates to verify the tree topology.
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2.3 Results:

Figure 2.1 Phylogenetic analysis of the HA sequence. The evolutionary history of
hemagglutinin (HA) nucleotide sequence of A/equine/Montana/9564-1/2015 was inferred
using the maximum likelihood method by MEGA 7.0, with a bootstrapping of 1000
replicates. The analysis involved 161 sequences of both canine and equine origin, and
canine H3N8 strains were shown as a collapsed branch. Different phylogenetic groups of
equine influenza virus (EIV) were color-coded and marked. Orange filled square = pre-
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divergence; Green filled circle = Eurasian; pink filled diamond = American lineage
(Kentucky + Argentina); Blue filled triangle = Florida sub-lineage Clade 2; Red Open
square = Florida sub-lineage Clade 1. Bootstrap values are shown at each node and
A/equine/Montana/9564-1/2015 is highlighted in red.

Figure 2.2 Phylogenetic analysis of the NA sequence. The evolutionary history of
neuraminidase (NA) nucleotide sequences of A/equine/Montana/9564-1/2015 was
inferred using the maximum likelihood method by MEGA 7.0, with a bootstrapping of
1000 replicates. The analysis involved 161 sequences of both canine and equine origin,
and canine H3N8 strains were shown as a collapsed branch. Different phylogenetic
groups of EIV were color-coded and marked. Orange filled square = pre-divergence;
Green filled circle = Eurasian; pink filled diamond = American lineage (Kentucky +
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Argentina); Blue filled triangle = Florida sub-lineage Clade 2; Red Open square = Florida
sub-lineage Clade 1. Bootstrap values are shown at each node and
A/equine/Montana/9564-1/2015 is highlighted in red.

Figure 2.3 Phylogenetic trees of PB2, PB1, NP, NA, M and NS sequences.Phylogenetical
analyses of nucleotide sequences of PB2, PB1, PA, NP, M, and NS segments of
A/equine/Montana/9564-1/2015 were inferred using the maximum likelihood method by
MEGA 7.0 [48], with a bootstrapping of 1000 replicates. The analysis involved EIV
sequences of both canine and equine origin, and canine H3N8 strains were shown as a
collapsed branch. Subtrees, involving Florida sub-lineage Clade 1 (Red open square) and
Florida Clade 2 (Blue filled triangle) viruses, are shown. Bootstrap values are shown at
each node and A/equine/Montana/9564-1/2015 is highlighted in red.
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2.3.1 BLAST Analysis
The sequences of the eight segments—polymerase basic protein 2 (PB2), polymerase
basic protein 1 (PB1), polymerase acidic (PA), hemagglutinin (HA), nucleoprotein (NP),
neuraminidase (NA), matrix (M1 and CM2), and non-structural proteins (NS1, NS2)—
were obtained in full length, and sizes were 2341, 2274, 2151, 1762, 1572, 1410, 982,
and 838 nucleotides (nt) respectively. Only the NA segment was nearly complete, with
20 and 30 nt missing at the 5′ and 3′ terminal regions, respectively. The sequences were
submitted to GenBank and accession numbers were assigned: MG198996 (PB2),
MG198997 (PB1), MG198998 (PA), MG198999 (HA), MG199000 (NP), MG199001
(NA), MG199003 (M), and MG199003 (NS). The BLASTn search analysis, optimized
for highly similar sequences (megablast) for all the eight segments of
A/equine/Montana/9564-1/2015, demonstrated the highest percentage identity to the
H3N8 strains of equine origin and not to any of the H3N8 strains of canine origin,
indicating the absence of any species cross over and intra-subtype genetic exchange.
A/equine/Montana/9564-1/2015 demonstrated equally high percentage identity to six
H3N8 strains isolated from Tennessee in 2014 (A/equine/Tennessee/4A/2014,
A/equine/Tennessee/27A/2014, A/equine/Tennessee/28A/2014,
A/equine/Tennessee/28B/2014, A/equine/Tennessee/29A/2014,
A/equine/Tennessee/30A/2014) and A/equine/Malaysia/M201/2015. Considering the
sequence similarity between these highly homologous strains, we used
A/equine/Tennessee/29A/2014 as a representative strain for BLASTn results and
phylogenetic analysis. A/equine/Montana/9564-1/2015 showed a percent identity score of
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99.78 (PB1), 99.81 (PA), 99.54 (HA), 99.87 (NP), and 99.8 (M) to
A/equine/Tennessee/29A/2014, while the PB2, NA and NS segments demonstrated
percent identities of 99.83, 99.93 and 100 respectively, to
A/equine/Malaysia/M201/2015. The HA segment of A/equine/Montana/9564-1/2015 also
showed percent identity scores of 99.23% and 99.18% with two strains from Malaysia,
A/equine/Malaysia/M201-2/2015 and A/equine/Malaysia/M201-1/2015. Overall,
A/equine/Montana/9564-1/2015 shared the highest percent identity with two equine
H3N8 viruses of Florida Clade 1 sub lineage, A/equine/Tennessee/29A/2014 and
A/equine/Malaysia/M201/2015.

2.3.2. Phylogenetic Analysis
To estimate the evolutionary history of A/equine/Montana/9564-1/2015, we performed
phylogenetic analyses of all the eight gene segments, with the currently available
sequences of both canine and equine H3N8 subtypes in the influenza virus resource
database (Bao et al., 2008; Chang et al., 2007). The EIV sequences we analyzed, included
the sequences from pre-divergence, Eurasian and American lineages (Kentucky and
South American sub-lineages) and Clades 1 and 2 of the Florida sub-lineage. The total
number of canine and equine sequences of H3N8 subtype, used to construct the
phylogenetic trees for each segment
were PB2 (124), PB1 (130), PA (120), HA (161), NP (122), NA (161), M (121)
and NS (121). For the phylogenetic analyses, we used a fixed number of nucleotides for
each gene
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segment: PB2 (2280), PB1 (2274), PA (2151), HA (1695), NP (1497), NA (1410), M (98
2), and NS (838).
The evolutionary history of the eight viral gene segments obtained by the phylogenetic
analyses was in complete agreement with the percent identity score obtained by
BLASTn, clustering with equine influenza A H3N8 viruses and not with canine H3N8
viruses. The evolutionary history of HA and NA segments of A/equine/Montana/95641/2015, was shown as complete trees, in which the different phylogenetic groups of EIV
were color-coded and grouped to describe the pre-divergence, Eurasian and American
lineages (strains from Kentucky and Argentina/South American sub-lineages), the Florida
sub-lineage and Clade 1 and Clade 2 viruses (Figure 2.1 and Figure 2.2). The
phylogenetic tree of the NA segment of our isolate, clustered with
A/equine/Malaysia/M201/2015 and A/equine/Tennessee/29A/2014 (Figure 2.2). A
similar cluster can be seen in the phylogenetic tree of HA. The HA segment of
A/equine/Malaysia/M201/2015 was not available in the database; however,
the HA segment of A/equine/Montana/9564-1/2015 clustered with another strain from
Malaysia, i.e., A/equine/Malaysia/M201-1/2015 along with
A/equine/Tennessee/29A/2014 (Figure 2.1). The oldest H3N8 EIV isolates, dated from
1963 to 1988, were grouped under the pre-divergence lineage and the isolates from
Europe and Asia from 1989 to 1994 were grouped under the Eurasian lineage (Fougerolle
et al., 2017). Isolates, dated from 1990 to 2001, that belonged to the Kentucky and
Argentina/South American sub-lineages, were grouped under American lineage, along
with Florida sub-lineage Clade 1 and Clade 2 viruses, isolated from 2005 to present
(Bryant et al., 2009; Lai, Rogers, Glaser, Tudor, & Chambers, 2004; Paillot, 2014).
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2.4 Discussion
EIV H3N8 epidemics have been reported worldwide, on a large scale, since the first
reported case of H3N8 occurred in Florida in 1963. Just like any other influenza epidemic
in the past, EIV epidemics occur in vaccinated and immunologically naïve populations, in
particular, H3N8 EIV epidemics can happen in horses of all ages, regardless of
vaccination status (Alves Beuttemmuller et al., 2016; Guthrie, 2006; Paillot & El-Hage,
2016; Pusterla et al., 2015). Vaccination breakdowns have been associated with EIV
outbreaks in the past, as documented in thoroughbred yearlings in Kentucky, and several
other parts of the world, including France and Ireland and horses imported into South
Arabia and Japan (Pusterla et al., 2015).
According to the OIE Expert Surveillance Panel on Equine Influenza Vaccine
Composition, the year 2015 witnessed an increased activity in H3N8 EIV cases, reported
from 46 premises over 23 states in the USA (Office International des Epizooties (OIE)
Conclusions and Recommendations, 2017). In 2016, 30 confirmed EIV cases were
reported from 16 states (Office International des Epizooties (OIE) Conclusions and
Recommendations, 2017). Unfortunately, there is no vaccination data available on these
outbreaks from the USA. In 2015–2016, EIV outbreaks were reported in other parts of
the world, such as Ireland, Sweden, and the UK. The outbreaks reported in the UK
occurred in unvaccinated animals. As per the report, no cases have been reported from
Asia and South America during this period (Office International des Epizooties (OIE)
Conclusions and Recommendations, 2017). The OIE report also concluded that EIV
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H3N8 viruses isolated from the USA in 2016 were homologous to the isolates from 2015
and belonged to the Florida sub-lineage Clade 1 (FC1). On the other hand, viruses
detected from the UK in 2015–2016 were Florida sub-lineage Clade 2 (FC2) viruses. The
data we obtained from phylogenetic analysis were in complete agreement with this
observation.
The BLASTn analysis of all viral genome segments, except PB2, NA, and NS, showed
the highest percentage identity to six H3N8 EIV strains isolated from Tennessee in 2014.
Considering the percentage identity between these six highly homologous strains, we
used A/equine/Tennessee/29A/2014 as a representative strain for our phylogenetic
analysis. It was very difficult to conclude that this sporadic infection occurred from the
contaminated premises, as there were no other horses on the premises reported to have
EIV infection, according to available information to us. We also checked the influenza
virus database (https://www.ncbi.nlm.nih.gov/genomes/FLU/Database/nphselect.cgi?go=database, accessed 5 January 2018) to gather information on the EIV
isolates reported from North America from 2000 to 2017. It is noteworthy that, only 1/69
isolates (A/equine/Montana/9233/2007(H3N8)) have been reported from Montana during
the past 17 years. According to the report from the OIE Expert Surveillance Panel, EIV
cases occurred in the USA in 2015–2016 (Office International des Epizooties (OIE)
Conclusions and Recommendations, 2017). However, we could not find any
documentation of new recent EIV isolates from North America during 2015–2017, which
indicates either the new isolates are homologous to the old known strains or lack of
reporting of the new isolates. The phylogenetic analysis, using the maximum likelihood
algorithm, used all the available full-length sequences of H3N8 currently available in the
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database, of both equine and canine origins. The phylogenetic reconstruction of the
individual genes was in complete agreement with the BLAST results and
A/equine/Montana/9564-1/2015 clustered with FC1 viruses, originated in the USA. The
fact that PB2, NA, M, NS and HA segments clustered with
A/equine/Malaysia/M201/2015 (H3N8) is interesting, because Malaysia has been EIV
free since 1977 and this outbreak in 2015, which started as a sporadic case occurred in a
time frame, concurrent with the import of four racehorses
(http://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?reportid=19160,
accessed 5 January 2018). Historically, EIV originating from Asia and Europe, usually
clusters with Florida Clade 2 viruses. On the contrary, A/equine/Malaysia/M201/2015
clustered with Florida Clade 1 viruses, together with A/equine/Tennessee/29A/2014. It is
difficult to trace the time and means of introduction of A/equine/Malaysia/M201/2015 in
the USA. It is worth noting that the sequences currently available in the database for
A/equine/Malaysia/M201/2015 are only for four segments, i.e., PB2, NA, M, and NS.
Only HA sequence is available for A/equine/Malaysia/M201-1/2015. The BLASTn
percent identity score of M segment showed 99.8% and 99.59% to
A/equine/Tennessee/29A/2014 and A/equine/Malaysia/M201/2015, respectively. Had
there been all eight segments available, A/equine /Montana/9564-1/2015 might have
shown a higher sequence identity to A/equine/Malaysia/M201/2015 than Tennessee 2014
strains. Overall, A/equine/Montana/9564-1/2015 viral segments clustered with Florida
Clade 1 viruses, A/equine/Tennessee/29A/2014 and A/equine/Malaysia/M201/2015 and
hence, belong to the Florida Clade 1 group of equine influenza viruses.
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Overall, this study provided us insights about the evolutionary relationship of A/equine
/Montana/9564-1/2015 (H3N8) virus. A comprehensive genome-scale analysis of new
isolates is essential to understand the molecular evolution and phylodynamics of EIV,
which in turn would help in the strategic selection of vaccine strains, effective
surveillance, and control. Antigenic and genetic variations caused by evolutionary
processes play a critical role in determining the dynamics of host range and tropism of
influenza viruses. In vivo studies are needed to evaluate the cross-species transmissibility
of EIV H3N8 and its ability to cause infections and respiratory diseases in other
mammalian hosts, including humans.
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Chapter 3 Current Progress in Influenza B Virus Research
3.1 Introduction
Influenza viruses belonging to the Orthomyxoviridae family, are important viral
pathogens that can cause significant respiratory disease. Influenza A virus (IAV) and
influenza B virus (IBV) are the two types of influenza viruses that co-circulate in
humans.
IBV has a genome chain length of 14,639 nucleotides. Understanding the biology of the
11 encoded proteins of IBV encoded in this genome, and their differences from IAV, is
crucial in for vaccine research. This review discusses the peer-reviewed articles that have
been published on five IBV proteins in brief. Two lineages of IBV co-circulate in most
regions around the world, prompting the usage of the quadrivalent vaccine containing
two IBV strains every flu season to prevent vaccine mismatch. This review summarizes
the current understanding of the evolutionary dynamics and epidemiology of IBV which
help inform vaccine strategies and prevent IBV infections.
Isolated for the first time in 1940, IBV is thought to be primarily a human pathogen.
However, there is evidence that other non-human species are susceptible to IBV
infections as well. This review discusses these studies of natural and experimental
infections of IBV, followed by a summary of the current literature available on the
studies done in ferrets.
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3.2 IBV Proteins
The eight segments of the IBV genome encode 11 proteins [4]. There are three RNAdependent RNA polymerase subunits (PB1, PB2 and PA), hemagglutinin (HA),
nucleoprotein (NP), neuraminidase (NA), matrix protein (M1) and two nonstructural
proteins (NS1 and NS2). IBV also has two unique proteins NB and BM2, which are
encoded by segment 6 and segment 7, respectively (Hatta, Goto, & Kawaoka, 2004).
This review discusses the polymerase proteins, NP, NS-1, M1 and HA proteins in brief.
3.2.1 Polymerase Proteins of Influenza B virus (PB1, PB2 and PA)
PB1, PB2 and PA proteins are trimeric complexes that, along with the nucleoprotein
(NP), are essential for expression of the viral genome (Jambrina, Barcena, Uez, &
Portela, 1997). These viral RNA-dependent RNA polymerases play a role in the
transcription and replication of the IBV genome. Each polymerase protein has a nuclear
localization function. While PA and PB1 associate with the cytoplasm and the nucleus,
the PB2 protein locates exclusively to the nucleus (Deng et al., 2011).
Understanding the assembly and nuclear transport for the polymerase complex would
provide new avenues to develop therapeutics to fight IBV infections. An RNA synthesis
assay was developed that could be adapted to screen for polymerase inhibitors (Reich,
Guilligay, & Cusack, 2017). Small molecule compounds have also been identified that
inhibit the growth of IBV by inhibiting the binary complexes formed between the
polymerase units (Muratore et al., 2012).
During the initiation of viral mRNA synthesis, the RNA polymerase protein produces
capped RNA fragments by cleaving the host mRNAs (Wakai, Iwama, Mizumoto, &
Nagata, 2011). Studies done between the polymerase proteins of influenza A virus and
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IBV showed that there is an incompatibility between the subunits of both types of viruses
for RNA transcription and replication (Crescenzo-Chaigne, Naffakh, & van der Werf,
1999; Iwatsuki-Horimoto et al., 2008; Wunderlich et al., 2010). Analysis of the crystal
structure of IBV’s PB2cap shows affinity for m7GDP and GDP, unlike IAV’s PB2cap
which prefers m7GDP (Liu et al., 2015). In the IBV PB2cap.m7 GTP complex, the
methyl group is missing, and the guanine and ribose moieties are inverted around the
long axis of the base. These properties allow IBV to bind to a wider range of cap binding
structures compared to IAV (L. L. Xie et al., 2016).
Phylogenetic analysis of 20 IBV sequences revealed lineage-specific amino acid
substitutions in the three polymerase proteins. The three segments have maintained
separate lineages, which helps preserve the viral fitness (Dudas, Bedford, Lycett, &
Rambaut, 2014). Additionally, a functional association seems to exist between PA, NP
and M proteins as well as the PB1 and PB2 proteins (Hiromoto et al., 2000). Differences
in the topology of the PA gene phylogenetic tree showed that the polymerase genes don’t
co-evolve as a unit; there is significant reassortment between the viruses (Hiromoto et al.,
2000).
3.2.2 Nucleoprotein (NP)
NP, which is a critical component of the ribonucleoprotein complex of IBV, plays a role
in the transcription and replication of the viral genome. This basic protein consists of 560
amino acids and has a molecular mass of 62kDa. Containing a head, body and tail loop,
the RNA-binding groove is found at the end of the tetrameric structure (Ng et al., 2012).
Several structural differences exist between the nucleoprotein of IBV and IAV. The Nterminus of IBV’s NP, which is longer than IAV by 50 amino acids is not critical for the
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viral RNA’s transcription or replication. It was shown that the nuclear protein of IBV
could not be replaced by the NP of IAV. N-terminal deletions of amino acid residues in
the positions 51 and 69 in B/Ann Arbor/1/66 virus NP did not have any impact on the
nuclear accumulation of the protein. (Stevens & Barclay, 1998). The nucleoprotein of
IBV inhibits the replication and polymerase activity of IAV in a dose dependent manner.
A study conducted later looked at the role of the NP protein during viral infection instead
of protein expression like the previous studies. Contradicting results were seen, showing
that virus attenuation followed mutations in the viral NP protein. It was also seen that
mutation in the N-terminal region had an effect of the transcription and replication of the
virus during infection (Sherry, Smith, Davidson, & Jackson, 2014).
3.2.3 Non-Structural Protein 1 (NS1)
IBV induces the ISG15 protein during infection, which blocks the conjugation of ISG15
protein. The RNA-binding domain of the NS1 protein is responsible for this inhibition
(Yuan & Krug, 2001). When an embryonated chicken egg was infected with a mutant
virus that lacked the NS1 gene, viral growth was not supported. The mutant NS1-IBV
induced IFN-ß in human lung epithelial cells in higher levels than the wild-type virus,
indicating that NS1 protein has a function as a viral IFN antagonist (Dauber, Heins, &
Wolff, 2004). IBV’s NS1 protein can complement IAV and result in infection when
IAV’s NS1 is deleted. In the absence of other viral proteins, it was seen that IRF-3
nuclear translocation and IFN-ß promoter was still activated by the N terminal and C
terminal independently (Donelan et al., 2004). dsRNA-binding regions exist on IBV NS1
protein that form the binding epitope, which consists of conserved tracks of basic and
hydrophilic residues (Yin et al., 2007). An important study showed that the limited host
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range of IBV is caused in part due to the species-specific binding of the NS1 protein.
ISG15 protein, which is ubiquitin-like, is induced by the alpha/beta-interferon, and plays
an important role in antiviral activity against influenza. NS1 of IBV binds to human and
non-primate ISG15, but not mouse or canine ISG15. This shows the possibility of IBV
infecting non-human primates, but not mice or canines without adaptive mutations
(Sridharan, Zhao, & Krug, 2010). Further studies in other animals to show the role of
NS1 in ISGlylation would provide further insight in the biology of IBV and help in the
development of more accurate models (Versteeg et al., 2010).
The crystal structure of the N-terminal region of the NS1 protein in conjugation with
human ISG15 showed that this region interacts with a pair of ISG15 molecules (Guan et
al., 2011). A high affinity binding site is formed around the ISG15 protein’s N-terminal
domain and NS1 protein as a result of the low affinity binding between them (Li et al.,
2011). A novel RNA-binding site was discovered in the C-terminal domain of IBV that is
not present in IAV (Ma et al., 2016). 22 human proteins were such as DHX9, ILF3 etc.,
were found to interact with two RNA-binding domains of IBV NS1 protein. SNRNP200
was identified as a positive regulator caused by host IFN responses. ILF3 exhibited dual
roles in the induction of IFN and the replication of IBV (Patzina, Botting, Garcia-Sastre,
Randall, & Hale, 2017).
3.2.4 Influenza B Matrix Protein 2 (BM2)
Encoded by the 7th RNA genome segment, the BM2 protein is translated via a
termination-dependent initiation from a bi-cistronic mRNA in an open reading frame that
is +2 nucleotides from the matrix (M1 protein). BM2 protein is made up of a 7-residue
ectodomain, a 19-residue transmembrane domain, and an 82-residue cytoplasmic tail.
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Key residues in the transmembrane domain such as His19, Trp23 and His27 play a role in
BM2 activity and opening the channel (Otomo, Toyama, Miura, & Takeuchi, 2009;
Rouse, Carpenter, Stansfeld, & Sansom, 2009). The BM2 initiation codon overlaps with
the M1 termination codon, and this unique stop-start mechanism can be utilized to
express multiple proteins from one mRNA (Hatta, Kohlmeier, Hatta, Ozawa, &
Kawaoka, 2009). BM2 forms a tetrameric structure where the channel pore is surrounded
by four protein bundles (Balannik, Lamb, & Pinto, 2008).
Several studies showed that BM2 is an integral membrane protein that closely associates
with cellular proteins (Paterson, Takeda, Ohigashi, Pinto, & Lamb, 2003; Watanabe,
Imai, Ohara, & Odagiri, 2003). Similar to the M2 protein in IAV, the BM2 protein can
transform the pH of the trans-golgi network (Betakova & Hay, 2009). Its function as a
proton-selective ion channel was thought to help in uncoating the virus in virus-infected
cells. When transmembrane (TM) domain residues Ser9, Ser12, Phe13, Ser16, His19, and
Trp23 in the BM2 ion channel were mutated to cysteine, the greatest disruption in ion
channel function was observed (Taylor, Udo, Lamb, & Pinto, 2005). NMR spectroscopy
studies provided detailed structural information about the BM2 TM peptide which
contains a histidine in the tetrameric transmembrane (Williams, Shcherbakov, Wang, &
Hong, 2017; Williams, Tietze, Lee, Wang, & Hong, 2016).
To investigate BM2’s function, BM2 knockout viruses were generated using reverse
genetics. Initial studies showed that BM2 is essential for IBV replication and infectivity,
playing a role in the assembly of the viral ribonucleoprotein complex into the virion
(Hatta et al., 2004; Imai, Watanabe, Ninomiya, Obuchi, & Odagiri, 2004; Jackson,
Zurcher, & Barclay, 2004). The cytoplasmic domain of BM2 has been found to play a
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role in aiding the association of the M1 protein with lipid membranes and virion
morphology (Imai, Kawasaki, & Odagiri, 2008).
The growth of IBV and BM2 activity are not hindered by the antiviral drug amantadine.
The ion channel’s pore is lined with polar serine residues and not hydrophobic amino
acids, and this confers drug resistance to the BM2 protein. The use of more polar
compounds is essential in inhibiting BM2 and disrupting viral infectivity (Pinto & Lamb,
2006; Taylor et al., 2005). The BM2 proton channel is a good antiviral target: a
monoclonal antibody targeting the ectodomain of BM2 proton channel inhibited viral
replication (Y. J. Wang et al., 2010). DNA enzymes containing the 10-23 catalytic motif
against the RNA of IBV BM2 can effectively inhibit viral RNA replication. This makes
the DNA enzymes a good candidate to develop a therapeutic agent against IBV (Kumar
et al., 2013). It has also been shown that BM2 can replace IAV’s M2 protein to support
viral replication (Wanitchang, Wongthida, & Jongkaewwattana, 2016).
3.2.5 Hemagglutinin (HA)
The HA protein is a surface protein that binds to the sialic acid of the host cell in the
early stages of influenza infection. This receptor binding specificity of HA plays an
important role in determining the host range of the influenza virus.
It was shown that in cells of CV-1 origin carrying the SV40 genetic material, HA and
Neuraminidase (NA) proteins accumulate in the trans-golgi network, enabling HA to get
desialidated before the proteins migrate to the cell surface. In Madin-Darby Canine
Kidney cells, de-sialidation occurs on the cell surface (Luo, Nobusawa, & Nakajima,
2002). The NA protein removes sialic acid from the HA protein as well as cellular
glycolipids or glycoprotein, thereby preventing the aggregation of virus particles and
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permitting the release of virus from host cell receptors (Palese et al., 1974; Shibata et al.,
1993).
HA is a homotrimer, with each monomer HA0 composed of a globular head and stem.
The native HA0 is cleave by proteases HA1 contains the residues that form the receptor
binding pocket in the head. They facilitate interaction with the host cell. The stem
contains the fusion peptide that is necessary for cytosolic release. It is encoded by both
HA1 and HA2. HA2 is also conserved across IAV and IBV.
Homology modelling of the HA1 structure of Influenza B virus showed that two amino
acid types could be present at the position 269: Residue 269 is Pro in the Yamagata sub
lineage, unchanged since B/Lee/ 40, but Ser in all viruses of the Victoria sub-lineage.
This provides the signature for the two lineages into which the influenza B virus HA
bifurcated in 1978 (Hay et al., 2001). The cytoplasmic tail of Influenza B virus regulates
fusion depending upon the amino acid sequence. The hydrophobicity of a single amino
acid was important in syncytium formation. It was seen that Leucine was not essential for
HA-mediated fusion (Ujike, Nakajima, & Nobusawa, 2006).
The HA0 sequence has a dual functional constraint, i.e., to remain a suitable substrate for
host-encoded proteases and to maintain a functional fusion domain. Since HA0 cleavage
occurs extracellularly in all human influenza viruses, it is an appropriate target for
antibody response. Because of its functional constraints, the epitope is extremely well
conserved, providing the vaccine with broad specificity against all circulating influenza B
viruses. Three amino acids were found to be conserved, particularly site 197 in the
B/Victoria viruses that were analyzed (Pechirra et al., 2005).
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It was seen that amino acid variation, while highest at the surface positions, had no
relationship to the degree of variability in the HA loop. Compensatory changes are made
to neutralize charges in a loop (Tung, Goodman, Lu, & Macken, 2004). Acylation was
not significant in membrane fusion by, but the pore formation and pore dilation were
appreciably affected by the amino acid sequence of the cytoplasmic tail and the existence
of a single acylation site in cytoplasmic tail residue 578.

3.3 Epidemiology of the Victoria and Yamagata lineages
In a comprehensive epidemiological study conducted across 20 countries worldwide,
influenza B (IBV) data was analyzed for the seasons between 2000-2013. 20% of all
influenza cases reported in these countries were due to IBV, highlighting the importance
of IBV when studying the epidemiology of influenza infections (Caini et al., 2015).
Another study done for the Asia-Pacific region identified IBV to be the cause of 0% to
92% of laboratory-confirmed cases of influenza in a given season/year (Jennings et al.,
2018). Despite clear indications that IBV has a serious impact on human health, there is a
scarcity in literature about the epidemiology of this virus. Greater number of local studies
are required to better understand IBV’s burden (Tafalla, Buijssen, Geets, & NoordegraafSchouten, 2016).
Since 1983, two distinct evolutionary pathways have existed, changing the landscape of
IBV’s epidemiology (Rota et al., 1990). The B/Yamagata/16/88 and B/Victoria/2/87
lineages are genetically and antigenically distinct (Biere, Bauer, & Schweiger, 2010).
While Victoria-like viruses were prevalent worldwide in the 1980s, the Yamagata lineage
took over in the 1990s. In some parts of Asia, Victoria-like viruses circulated in the late
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1990s, but this lineage re-emerged globally in 2001. Co-circulation of both lineages was
seen during certain years. In seasons where IBV was predominant or co-circulating
alongside influenza A virus (IAV), Victoria lineage predominated 64% of seasons,
whereas Yamagata lineage predominated 36% of seasons (Caini et al., 2015).
Epidemiological dynamics of the Victoria and Yamagata lineages vary significantly.
Phylogenetic trees constructed from the HA genes showed that the Victoria lineage
comprised of a single tree-trunk that had several side branches which circulated for short
periods of time. The Victoria lineage undergoes greater positive selection pressure, which
makes the virus more likely to undergo antigenic drift. The Yamagata lineage is more
conserved than the Victoria lineage, with multiple clades circulating for longer periods of
time (Vijaykrishna et al., 2015).
Studies have shown the Yamagata viruses bind predominantly to α-2,6-linked sialic acid
host receptors whereas Victoria viruses bind to both α-2,3 and α-2,6 binding capacities.
This correlates to the different age distributions of humans that are susceptible to
infections by the two lineages, since children have a greater number of α-2,3 receptors
and a lower level of α-2,6 receptors compared to adults.
Thus, differences in the hemagglutinin binding preferences influence the phylodynamic
patterns of both lineages, with the Victoria lineage being more susceptible to seasonal
bottlenecks and antigenic selection. The Yamagata lineage is more likely to infect older
people and has lower transmission rates.
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3.4 Evolutionary dynamics of IBV
Understanding the evolutionary dynamics of influenza is essential for the prevention and
management of viral infection. Historically, emerging epidemic strains were classified by
antigenic analysis. Hemagglutination Inhibition assay may not always provide
information regarding evolutionary relationships as viruses from different lineages have
different amino acid substitutions at key positions which is not always reflected by
changes in the HI assay in terms of antigenic properties. Thus, performing a molecular
analysis of viral genes provides an insight into the epidemic potential of different strains
by allowing the identification of amino acid residues that contribute to antigenic drift.
Phylogenetic analysis also enables the identification of circulating strains belonging to
different lineages (Lindstrom et al., 1999; Rota et al., 1990).
Molecular analysis of circulating IBV strains in the 1998-2001 influenza seasons in
Quebec, Canada revealed distinct evolutionary patterns in the HA1, NS1 and NA protein
sequences. Isolates from 1998-1999 period were not closely related to the vaccine strain
(B/Harbin/7/94) of that year when a comparison of HA1 and NS1 sequences was done,
but similarities existed in the NA sequences (Abed, Coulthart, Li, & Boivin, 2003).
Analysis of isolates from 2001-2002 winter season in European countries such as
Belgium, Spain, Finland and Israel revealed the categorization of IBVs into the
B/Yamagata/16/88 or B/Victoria/2/87 lineages. The appearance of B/Victoria/2/87
lineage viruses marks the spread of this lineage from Asia to Europe, with Israel being a
possible geographic route. Progression of the flu season led to a dominance of B/Hong
Kong/1351/02-like viruses in these countries aided by the advantages of reassortment
(Chi, Bolar, Zhao, Rappaport, & Cheng, 2003). The Yamagata lineage, on the other
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hand, dominated Beijing, China in 2013-2014. While HA segments were derived from
the Yamagata lineage, NA segments were derived from the Victoria lineage, showing the
reassortment had an important role in the evolution of IBVs in this region as well (Fang
et al., 2015).
Phylogenetic analysis of IBV isolates from the years 2004-2012 in Taiwan provided
insight into the evolutionary processes that cause a persistent virus to become
predominant. HA sequences from 2007 to 2012 were used to track epidemiological
changes in TW08-I which caused an epidemic in the 2011-2012 influenza season in
Taiwan. Drift mutations were seen in several gene segments of Yamagata lineage viruses
derived from TW08-I (Yang et al., 2012).
Surveillance of IBV strains from 1996-2012 in Sao Paulo, Brazil was conducted. Some
years had either Victoria or Yamagata lineages viruses dominating, whereas other years
like 2005, 2006 and 2008 saw a cocirculation of both lineages. This alternating pattern
could be the cause of decrease in vaccine match that is observed, highlighting the need
for quadrivalent vaccines containing strains from both lineages of IBV (Paiva et al.,
2013). Similar studies in Riyadh, Saudi Arabia during 2010-2011and Italy during 20102015 point to co-circulation of the Victoria and Yamagata lineages. Variations in the
amino acid sequences of HA and NA proteins of the circulating strains point to the need
for increased surveillance to discover newly emerging strains (Ali, Amer, & Almajhdi,
2014; Tramuto et al., 2016). Analysis of IBV strains between 1995-2008 in Malaysia
pointed at a dominant lineage (Victoria or Yamagata) that alternated every 1-3 years.
Specific amino acid substitutions in the HA segment and frequent introductions of both
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lineages into Malaysia was thought to contribute to this evolutionary pattern (Sam et al.,
2015).
Thus, distinct evolutionary patterns of IBV can be observed based on epidemiological
studies conducted in Europe, Asia and South America. The alternating dominance of
both lineages and their co-circulation in an influenza season are common. Reassortment
between circulating strains and drift mutations that affect the antigenicity of the viruses
contribute to IBV evolution. Gaining a better understanding of IBV’s epidemiology can
inform antiviral therapies and vaccine formulation to combat its infection.

3.5 Natural Occurrence of Influenza B in Non-Human Species
The first evidence of influenza B infection in pigs was observed in 1966 in Budapest,
Hungary, where influenza B outbreaks in humans resulted in cough, serous nasal
discharge and conjunctivitis in pigs. Analysis of eight infected farms was done by
collecting 924 swine serum samples, and in four farms 8 to 24 percent of pigs had a HI
antibody titer to IBV. However, direct reproduction of IBV in the respiratory tract was
not observed (Takatsy & Farkas, 1969). Earlier this year, a study done in Taiwan showed
the first evidence of natural IBV-infected swine in a clinical setting. Genetic
characterization of the IBVs showed that they belonged to the B/Brisbane/60/2008
genetic clade of Victoria. This was considered to be a sporadic case of IBV transmission
from humans to pigs (Tsai & Tsai, 2019). There is also a report of IBV isolation from
horses as mentioned by Kawano and group, but the article could not be accessed
(Kawano J, 1978).
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In 1971, IBV that resembled B/Victoria/98926/70 was isolated from a 2-month-old
Dachshund in Taipei city. This was the first Influenza B virus isolate of canine origin
obtained under natural conditions (Chang CP, 1976). Failure to re-isolate the virus or
obtain a HI antibody titer one month later caused Chang CP et. al. to conclude that the
virus failed to produce an antigenic response in the dog or that the dog might have
contracted the virus from infected humans whom it shared a close contact with. Zoo and
migratory birds in Hungary had an outbreak due to IBV infection. 4.1% of the animals
tested had IBV antibodies, demonstrating the susceptibility of avian species to IBV
(Romvary, Meszaros, & Barb, 1980).
In the spring of 1999, 12 juvenile harbor seals (Phoca vitulina) that were stranded near
the Dutch coast had respiratory problems. Growth in cell culture, electron microscope
analysis and subsequent reverse transcriptase polymerase chain reaction confirmed the
presence of IBV in these animals. Lower viral shedding and delayed IgG antibody
response to HA and NA was observed. Phylogenetic analysis indicated a lack of genetic
or antigenic drift of IBV in seals. This influenza B/Seal/Netherlands/1/99 virus was
similar to strains that circulated in humans 4 or 5 years earlier (Fouchier, Bestebroer,
Martina, Rimmelzwaan, & Osterhaus, 2001). This was the first evidence of IBV in seal
populations, highlighting the possibility of seals being an animal reservoir that new IBVs
can emerge from. Virus attachment was seen in the epithelial cells of the respiratory tract
in seals, consistent with the previously mentioned study (Ramis, van Riel, van de Bildt,
Osterhaus, & Kuiken, 2012).
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3.6 Seroprevalence studies of IBV in Non-Human Species
A study done in Japan in 1978 indicated that antibodies to Influenza B virus were present
in 16 out of 504 horse sera and 1 out of 1030 swine sera (0.1%) that were tested. All the
positive horses were born in 1976, which was the same year that a human outbreak of
influenza B occurred. It was therefore suggested that these horses might be infected from
man (Kawano J, 1978). In 2000, sera collected from 971 seals showed a prevalence of
antibodies to Influenza B virus in 2% of the animals after 1995, but none before 1995.
Wild pigs in Croatia were positive for hemaggutination-inhibition (HAI) antibodies
against virus B/Beijing/184/93-like strain in 68 (67.32%) samples in a study conducted in
the same year (Zupancic et al., 2000). Two years later, antibodies to Influenza B virus
were found in serum samples collected from Caspian seals (Phoca Caspica). 14% of
samples collected in 1997 and 10% of samples collected in 2000 were detected positive
by ELISA (Ohishi et al., 2002). HAI titers to Influenza B virus was observed in cervid
sera from Croatia. 31% of free-ranging and 54% of captive cervids that were studied had
an antibody titer of >1:20 (Zupancic et al., 2002).
Indirect evidence of Influenza B virus was also seen in South American fur seal
(Arctocephalus australis) samples in Uruguay. This was the first evidence of IBV in this
species (Blanc et al., 2009). In 2013, serum samples from harbor seals and gray seals
living in Dutch coastal waters during 2002-2012 were analyzed. It was shown that 9 out
of 21 samples collected in 2010 were positive, whereas only 1 out of 150 samples was
positive in 2011. This study showed that seals were infected by a virus closely
resembling B/Yamanashi/166/98, but antigenically different from B/Seal/
Netherlands/1/1999 (Bodewes et al., 2013).
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3.7 Cell cultures utilized in the study of IBV
Cell cultures are widely used for the production of influenza vaccines. Vaccine
manufacturers use several continuous cell lines, amongst which Madin-Darby Canine
Kidney (MDCK) cells are the most extensively used. Guinea pig serum was seen to
inhibit the infectivity of IBV grown in chick embryo or MDCK cells (Yamamoto et al.,
1987). It was seen that viral envelope of IBV was disrupted, degrading the M1 protein
and genomic RNA (Goshima et al., 1988). However, cell cultures derived from the
organs of animals, known as primary cell cultures, offer several advantages. Although
they have limited growth in vitro, they represent an environment closest to the in vivo
condition. Use of primary cell cultures can help inform in vivo studies or eliminate the
need for them depending on the study’s requirements. Primary cells from several nonhuman species have been used to study IBVs.
Primary ferret kidney cell cultures exhibited cytopathic effects when infected with four
different strains of IBV in 1970 (Johnson & Schieble, 1970). The metabolic activity of
seven different IBV strains was measured using hamster tracheal organ cultures
(Gurevitz, Schulze, Swierkosz, Arens, & Schwarz, 1987). Ferret airway cells inoculated
with IBV and IAV from different lineages also supported efficient replication with little
variation between the strains. Lower titers were observed in the cells infected with IBV
compared to IAV (Elderfield et al., 2015).
Mink lung epithelial cells contain alpha-2,6 and alph-2,3 receptors, which are essential
for the entry of influenza virus, at levels that are similar to MDCK cells. A mink lung
epithelial cell line was created which supported IBV infection (Schultz-Cherry, Dybdahl-
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Sissoko, McGregor, & Hinshaw, 1998). Chick embryo brain cultures supported the
replication of influenza B viruses when enriched with neurons or astroglial cells (Parker,
Spence, & OCallaghan, 1997).

3.8 Use of Ferrets and Other Non-Human Species to Study IBV
The ferret is a widely used animal to study the replication, transmission and pathogenesis
of Influenza A viruses. Several clinical symptoms and laboratory signs are similar when
ferrets and humans are infected with human or avian IAV. Unlike mice which require
attenuation, ferrets are naturally infected with IBV. The sialic acid receptors in the
respiratory tract of both species are comparable, making ferrets a useful animal to model
human or avian influenza infection. Additionally, transmission and seroconversion of
IAV has been detected in ferrets.
In contrast, experimental infections of IBV in ferrets have been few. Ferrets were used to
study the metabolic changes occurring during convalescence from IBV infection. One
study indicated an alteration in the lipid metabolism 24 hours after dissemination of the
virus during convalescence (Kang, Galloway, Bean, Cook, & Olson, 1991). Another
study looked at the hepatic lipid disturbances and ferrets as a possible model to study the
steatosis of Reye’s syndrome (Kang et al., 1991).
Ferrets have also been used to study the effect of antiviral agents of IBV infection.
Single-dose treatments of 2'-FluorodGuo and 2'-FluorodDAP in ferrets infected with
B/Singapore/222/79 inhibited viral replication in the upper respiratory tract, although the
response was reduced in comparison to ferrets infected with IAV (Jakeman, Tisdale,
Russell, Leone, & Sweet, 1994). The ability of peramivir, an influenza neuraminidase
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(NA) inhibitor, to block IBV infection was tested in ferrets. A single intravenous
infection of peramivir was seen to lower viral titers and symptoms in ferrets following
infection with IBV (Kitano et al., 2011). The fitness of neuraminidase resistant IBVs was
studied in ferrets to obtain a better understanding of the public health threat that they
could pose (Pascua et al., 2016). In order predict the amino acid substitutions that may
arise when IBV strains are under prolonged exposure to zanamivir, a neuraminidase
inhibitor, IBV was passaged in vitro under zanamivir pressure. A NA mutation E117D
was identified that conferred resistance, but caused decreased viral replication in ferrets
(Oh et al., 2018).
Studies comparing IAV and IBV infections in ferrets showed that lower pathogenesis was
seen in IBV-infected ferrets compared to IAV. Milder clinical symptoms were thought to
be the result of lower viral replication in the lungs. This reduced viral replication was also
implicated in the lower induction of inflammatory cytokines TNF-a and IFN-a (Y. H.
Kim, Kim, Cho, & Seo, 2009). Another study used an outbred ferret model to model the
genetic diversity in humans. Infection of these outbred ferrets with multiple IAV and IBV
strains showed that the mildest clinical symptoms were observed in IBV strains. The
disease severity was correlated to the antibody response in the upper respiratory tract of
ferrets. (Huang et al., 2011).
The expression of immune molecules such as cytokines, chemokines, and immune
mediators was studied in the upper respiratory tract (URT) of ferrets infected with IAV
(H1N1 pdm09 and H3N2) and IBV. Interleukin-1, alpha interferon, and tumor necrosis
factor alpha mRNAs levels were correlated to a peak in the viral titers. This study
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demonstrated the similarities in the localized immune responses in ferrets when infected
with IAV or IBV (Carolan et al., 2016).
Experimental infection of ferrets with two B/Victoria (B/Brisbane/60/2008 and
B/Bolivia/1526/2010) and two B/Yamagata (B/Florida/04/2006 and
B/Wisconsin/01/2010) was done to study clinical and pathological profiles. The clinical
illness caused by B/Brisbane/60/2008 was the most severe. B/Brisbane/60/2008 also
caused higher viral burden compared to viruses belonging to the B/Yamagata lineage and
established an infection in the lower respiratory tracts of the ferrets. (Huang et al., 2014).
B/Florida/04/2006 virus was serially passaged in mice until very virulent, and then
infected in ferrets. The mouse-adapted virus replicated in the upper and lower respiratory
tracts of ferrets. This was the first study to show successful ferret-to-ferret transmission
of IBV in contact and droplet conditions (E. H. Kim et al., 2015). Transmission of IBV
between ferrets was not affected by the absence of the NB membrane protein, showing
that the NB protein is not responsible not replication or transmission of IBV via
respiratory droplet exposure in the in vivo ferret model (Elderfield et al., 2016).
Some studies using ferrets were done to aid in vaccine research (Sun et al., 2019). 5-6
months old ferrets were used to study whether the live attenuated influenza vaccine
(LAIV), which contains IBV components, would offer cross-protection against the
different lineages. Ferrets vaccinated with monovalent LAIV had a lower level of
challenge virus compared to the unvaccinated ferrets (Kiseleva et al., 2018).
3.9 Experimental IBV infections in other species
The susceptibility of domestic pigs to Influenza B virus was demonstrated in 1966 when
piglets that were intranasally injected with B/Budapest/10/65 demonstrated antibodies
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and infected naïve animals by contact transmission (Takatsy & Farkas, 1969). In 2015, an
experimental challenge in pigs showed that B/Brisbane/60/2008 (Victoria lineage) and
B/Yamagata/16/1988 (Yamagata lineage) caused symptoms and influenza-like lesions.
B/Brisbane/60/2008 transmitted successfully to sentinel animals.
An experimental infection involving monkeys and cats showed that these animals are
susceptible to Influenza B virus infection by intranasal instillation, but evidence of
contact transmission was not clearly established. The dogs included in this study were not
susceptible to IBV infection (Paniker & Nair, 1972). SPF hamsters were infected with
different strains of IBV to study the differences between wild type and cold adapted
strains (Reeve, Pibermann, & Gerendas, 1981).
Guinea pigs were infected intranasally with IBV and an adjuvant. High levels of
hemagglutination-inhibiting antibodies and neutralizing antibodies demonstrated the
utility of this scheme in setting up immune sera for in vitro diagnosis (Havlickova,
Prokesova, Zanvit, Tacner, & Limberkova, 2006). Influenza B viruses belonging to both
B/Victoria-like and B/Yamagata-like lineages were shown to replicate in the respiratory
tract of guinea pigs in an experiment. Injection showed and mental infection.
Aerosol/droplet transmission was observed, with higher efficiency at 5°C compared to
20°C (Pica, Chou, Bouvier, & Palese, 2012). Guinea pigs were vaccinated with
neuraminidase intramuscularly and intranasally to study the ability of recombinant
neuraminidase vaccination to prevent viral infection. The vaccinated animals were
susceptible to infection via contact and air borne transmission routes, although the viral
titers were lowered. Intranasal vaccination prevented virus transmission to naïve animals
(McMahon et al., 2019).
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Report of lack of attachment of influenza B virus to trachea and bronchi of cetaceans is
consistent with absence of reported influenza B virus infections in these species
(Zupancic et al., 2002).
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Chapter 4 Replication Kinetics of IBV in Swine Primary Respiratory Epithelial
Cells
4.1 Abstract
Influenza B virus (IBV) is a respiratory pathogen that poses a significant burden to
human health. Humans are the sole reservoir of IBV, however there is evidence to show
that swine are susceptible to IBV. In this study we infected swine primary respiratory
epithelial cells with B/Brisbane/60/2008 (BR08), B/Florida/04/2006 (FL06), B/Hong
Kong/286/2017 (HK17) and B/Utah/09/2014 (UT14) at 0.01 and 0.1 multiplicities of
infection (MOI). Experiments were conducted at 33°C and 37°C, representing the
temperatures of the upper and lower respiratory tract, respectively.

4.2 Introduction
Influenza B virus (IBV) is a respiratory pathogen belonging to the Orthomyxoviridae
family. While IBV’s closest relative influenza A virus (IAV) predominates globally in
terms of disease prevalence and severity, IBV also has a significant impact on the overall
burden of influenza disease (W. P. Glezen, Schmier, Kuehn, Ryan, & Oxford, 2013).
37% of the total healthcare costs due to influenza illness for the seasons 2001/2002 to
2008/2009 was attributed to IBV (Yan, Weycker, & Sokolowski, 2017).
IBV diverged into two separate lineages in the 1980s. The antigenically distinct lineages
were named Victoria and Yamagata after B/Yamagata/16/88 and B/Victoria/2/87, which
were the original isolates (Rota et al., 1990). While the Victoria lineage viruses only have
one genetic clade, the B/Brisbane/60/2008 which is viewed as Group 1 of IBV, the
Yamagata lineage viruses are divided into two clades. Group 2 in the Yamagata lineage is
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represented by B/Brisbane/3/2007, and Group 3 is represented by
B/Bangladesh/3333/2007. One lineage usually predominates in any given year, but
viruses of both lineages often co-circulate during a flu season (Caini et al., 2015).
Victoria-like viruses dominated in the late 1980s, and Yamagata lineage was predominant
in the 1990s. The Victoria lineage re-emerged worldwide in 2001 (R. B. Chen & Holmes,
2008). Specific nucleotide substitutions in the hemagglutinin (HA) of IBV characterize
the specific lineage and groups within lineages (Arvia, Corcioli, Pierucci, & Azzi, 2014).
Reassortment between and within the Victoria and Yamagata lineages can generate
viruses having genetic variation that may affect viral antigenic properties (R. B. Chen &
Holmes, 2008).
Although IBV has established itself primarily as a human pathogen, there is serological
evidence of IBV in several other mammalian species. IBVs have been isolated in dogs,
pheasants, horses, and pigs although in several studies the criteria to establish infection
were not met (Chang CP, 1976; Kawano J, 1978; Romvary et al., 1980; Zupancic et al.,
2000; Zupancic et al., 2002). IBV was shown to cause an infection and circulate in harbor
seals (Phoca vitulina) and gray seals (Halichoerus grypus) (Bodewes et al., 2013).
Serving as a natural host for influenza viruses, pigs can be infected with both avian and
human influenza viruses. The porcine respiratory tract possesses both sialic acid α2,3galactose (SAα2,3-Gal) linked receptors and α2,6-galactose (SAα2,6-Gal) linked
receptors (Ito et al., 1998). Swine, avian and human influenza viruses can undergo
reassortment in pigs, resulting in novel influenza viruses. These novel viruses may
contain mutations that allow transmission to humans thereby establishing a human
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infection. They may otherwise maintain infection in pigs, making them a reservoir for
human infection. Pigs thus play an important role in the ecology of influenza viruses.
Antibodies to IBV in pigs have been detected in some studies, but the susceptibility of
domestic pigs to Influenza B virus was demonstrated in 1968 when piglets that were
intranasally injected with B/Budapest/10/65 demonstrated antibodies and infected naïve
animals by contact transmission. Little or no clinical illness was observed (Takatsy &
Farkas, 1969). In 2015, an experimental study was done which showed that IBV from
both lineages can infect and replicate in pigs. IBV transmission was observed in pigs that
were infected with viruses belonging to the Victoria lineage (Ran et al., 2015).
Cell cultures form an important platform for vaccine production for influenza viruses.
Factors such as the sialic acid receptors distribution and cellular environment affect the
ability of different cell lines to replicate in influenza viruses (Rott, 1992). Continuous cell
lines like Madin-Darby Canine Kidney (MDCK) cells have been used extensively for
influenza studies. Insufficient antiviral defense in MDCK cells promotes efficient
replication of IBV (Frensing et al., 2011). African green monkey kidney (Vero) cell line
and HeLa cell lines (immortal cell line derived from cervical cancer cells) are other
continuous cell lines that provide an alternate host system to study IBV pathogenesis and
infection biology (Govorkova, Murti, Meignier, deTaisne, & Webster, 1996; Yamanaka,
Shirasawa, & Yoshizawa, 1995).
Primary cells closely resemble the in vivo characteristics of the susceptible host they are
derived from. Exhibiting mitotic activity in the first 2-4 weeks, they have a limited
growth capacity in vitro compared to transformed cells (Petursson & Fogh, 1963).
Primary epithelial cells from several species have been used to gain a better
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understanding of influenza-host interactions (Castleman & Hancock, 2014; Fischer,
Sidhaye, King, Lane, & Pekosz, 2010; Newby, Rowe, & Pekosz, 2006; H. Y. Wang et al.,
2018; Zeng et al., 2019; Zeng et al., 2013; Zhao, Liang, & Ji, 2011). Moreover, primary
epithelial cells of swine origin are used to study the infection models of various diseases
including influenza (Allen C Bateman et al., 2010; Guseva, Knight, Whittimore, &
Wyrick, 2003; Kasza, Bohl, & Jones, 1960; Schierack et al., 2006).
Mink lung epithelial cells actively supported the replication of IBV to titers comparable
to MDCK cells (Schultz-Cherry et al., 1998). Chick embryo brain cultures too supported
the replication of influenza B viruses when enriched with neurons or astroglial cells
(Parker et al., 1997). It was also seen that ferret tracheal epithelial cells when infected
with IBV showed productive replication (Elderfield et al., 2015). Our lab previously
demonstrated that swine primary respiratory epithelial cells derived from a day-old
gnotobiotic piglet could be infected with four types of influenza viruses (Sreenivasan et
al., 2019).
This study looked the replication kinetics of IBV in swine primary respiratory epithelial
cells derived from the nasal turbinate, trachea and lung cells of a day-old gnotobiotic
piglet at different multiplicities of infection of the virus. The primary cells were infected
with IBV strains belonging to both Victoria and Yamagata lineages. Temperature
dependent replication of IBV was seen at both 33°C and 37°C. B/Hong Kong/286/2017
(Victoria lineage) grew to the highest titers in nasal turbinate and lung primary epithelial
cells.
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4.2 Materials and Methods
Swine primary nasal turbinate, trachea and lung cells were isolated from a day old
gnotobiotic piglet. These cell types were developed and characterized as described by
Sreenivasan et. all (Sreenivasan et al., 2019). The primary cells were grown in
Dulbecco’s Modified Eagle Medium (DMEM/F-12), 10% FBS (PAA Laboratories Inc.,
Dartmouth, MA, USA) and penicillin-streptomycin (100 U/mL) (Life Technologies,
Carlsbad, CA, USA), Mouse epidermal growth factor (EGF) (Sigma (5 ng/mL)), insulin
(5 µg/mL) transferrin (5 µg/mL) and selenium (5 ng/mL) (Sigma). All cell cultures were
maintained in a humidified incubator at 37°C or 33°C with 5% CO2. The primary cells of
passages 2 to 10 were used for this study.
4.2.1 Culture of Influenza B viruses
The Influenza B viruses used in this study were B/Brisbane/60/2008 (BR08),
B/Florida/04/2006 (FL06), B/Hong Kong/286/2017 (HK17) and B/Utah/09/2014 (UT14).
For this study, MDCK cells were maintained in Dulbecco’s Modified Eagle medium,
supplemented with 10% fetal bovine serum (FBS) (PAA Laboratories Inc., Dartmouth,
MA, USA) and penicillin-streptomycin (Life Technologies, Carlsbad, CA, USA) (100
U/mL). MDCK cells were cultured in the T-25 flask, inoculated with the virus inoculum
at 0.01 multiplicity of infection (MOI) and incubated at 37°C in 5% CO 2 for 1 h. After
infection, the virus growth medium, containing fresh DMEM with 0.3% bovine serum
albumin (BSA) made from 6% stock, 1 μg/mL tolylsulfonyl phenylalanyl chloromethyl
ketone (TPCK)-treated trypsin (Sigma, Saint Louis, MO, USA) and penicillinstreptomycin (100 U/mL) (Life Technologies, Carlsbad, CA, USA), was added for
further incubation at 37°C in 5% CO2 for 72 h. The infected cell cultures were freeze-
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thawed. For removal of cellular debris, the supernatant was spun at 500× g for 10 min at
4°C. The viruses were stored at -80°C until further use. The Reed and Muench method
was applied to determine the virus titers (50% cell culture infectious dose (TCID50)
endpoint dilution assay) in MDCK cells (Reed & Muench, 1938a).
4.2.2 Replication Kinetics
Approximately 2 × 105 cells/well were seeded on 24 well plates. The cells were
respectively infected with B/Brisbane/60/2008 (BR08) or B/Florida/04/06 (FL06) or
B/Hong Kong/286/2017 (HK17) or B/Utah/09/2014 (UT14). Virus growth medium for
primary cells included Opti-MEM (Thermofisher Scientific, Waltham, MA), 0.001%
(0.01 µg/ml) TPCK Trypsin (Pierce, Thermofisher Scientific, Waltham, MA), and 1%
antibiotic-antimycotic (Thermofisher Scientific, Waltham, MA). MDCK cells were
infected at the same MOI, with DMEM, 0.1% (1 µg/ml) TPCK Trypsin (Pierce,
Thermofisher Scientific, Waltham, MA), and 1% antibiotic-antimycotic (Thermofisher
Scientific, Waltham, MA). Samples were collected at 24 h intervals until 120 h post
infection.
Approximately, 1 × 104 MDCK cells were seeded on flat bottom 96 well plate (Greiner
bio-one, NC, USA) and incubated overnight. Serial ten-fold dilutions of the samples were
prepared in virus infection media and were inoculated on pre-seeded MDCK 96-well cell
culture plates. The inoculated plates were incubated for 5 days at respective temperatures.
The infectivity of the virus was determined by hemagglutination assay using 1% Turkey
red blood cells (Lampire Biological Laboratories, Pipersville, PA, USA). Titers were then
calculated using Reed and Muench formula (REED & MUENCH, 1938b).
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4.3 Results

a

b

Figure 4.1 Morphology of porcine primary respiratory epithelial cells. Panel (a) shows
uninfected nasal turbinate, trachea and lung primary cells under a phase contrast
microscope (20x). Panel (b) shows nasal turbinate, trachea and lung primary cells
infected with B/Hong Kong/286/2017 (72h post-infection) under a phase contrast
microscope (10x).
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Figure 4.2 Swine primary nasal turbinate epithelial cells were infected with (a) 0.01 MOI
or (b) 0.1 MOI of B/Brisbane/60/2008 (BR08) or B/Florida/04/2006 (FL06) or B/Hong
Kong/286/2017 (HK17) or B/Utah/09/2014 (UT14) at 33°C and 37°C. Virus titers were
expressed in log10TCID50/ml. Dotted line represents the replication kinetics at 33°C.
Data shown here are representative of two independent experiments performed in
triplicates ± SE.
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Figure 4.3 Swine primary trachea epithelial cells were infected with (a) 0.01 MOI or (b)
0.1 MOI of B/Brisbane/60/2008 (BR08) or B/Florida/04/2006 (FL06) or B/Hong
Kong/286/2017 (HK17) or B/Utah/09/2014 (UT14) at 33°C and 37°C. Virus titers were
expressed in log10TCID50/ml. Dotted line represents the replication kinetics at 37°C,
while the bold line represents the kinetics at 33°C. Data shown here are representative of
two independent experiments performed in triplicates ± SE.
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Figure 4.4 Swine primary lung epithelial cells were infected with (a) 0.01 MOI or (b) 0.1
MOI of B/Brisbane/60/2008 (BR08) or B/Florida/04/2006 (FL06) or B/Hong
Kong/286/2017 (HK17) or B/Utah/09/2014 (UT14) at 33°C and 37°C. Virus titers were
expressed in log10TCID50/ml. Dotted line represents the replication kinetics at 37°C,
while the bold line represents the kinetics at 33°C. Data shown here are representative of
two independent experiments performed in triplicates ± SE
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Figure 4.5 MDCK cells were infected with (a) 0.01 MOI or (b) 0.1 MOI of
B/Brisbane/60/2008 (BR08) or B/Florida/04/2006 (FL06) or B/Hong Kong/286/2017
(HK17) or B/Utah/09/2014 (UT14) at 33°C and 37°C. Virus titers were expressed in
log10TCID50/ml. Dotted line represents the replication kinetics at 37°C, while the bold
line represents the kinetics at 33°C. Data shown here are representative of two
independent experiments performed in triplicates ± SE
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Virus
BR08
FL06
HK17
UT14

Max. Titer Log10TCID50/ml (33˚C )
MDCK (5.36) > Trachea (3.43) > NT (3.35) > Lung (2.43)
MDCK (3.94) > Trachea (3.45) > NT (3.37) > Lung (2.9)
MDCK (4.51) > NT & Trachea (4.36) > Lung (4.33)
Trachea (4.39) > MDCK (4.34) > Lung (3.4) > NT (3.29)

Virus
BR08
FL06
HK17
UT14

Max. Titer Log10TCID50/ml (33˚C )
MDCK (5.36) > Trachea (3.43) > NT (3.35) > Lung (2.43)
MDCK (3.94) > Trachea (3.45) > NT (3.37) > Lung (2.9)
MDCK (4.51) > NT & Trachea (4.36) > Lung (4.33)
Trachea (4.39) > MDCK (4.34) > Lung (3.4) > NT (3.29)

Table 4.1 shows the peak viral titers (log10TCID50/ml) B/Brisbane/60/2008,
B/Florida/04/06, B/Hong Kong/286/2017 and B/Utah/09/2014 grew to in nasal turbinate,
trachea, lung and MDCK cells in decreasing order of titers at 33˚C and 37˚C at 0.01
multiplicity of infection.
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Peak Titer Log10TCID50/ml (33˚C)

Virus
BR08

MDCK (5.35) > Lung (4.46) > Trachea (4.14) > NT (3.84)

FL06

MDCK (5.57) > Trachea (5.38) > NT & Lung (4.25)

HK17

Lung (4.47) > MDCK (4.45) > NT (4.31) > Trachea (3.42)

UT14

MDCK (5.40) > Trachea and Lung (4.34) > NT (3.99)
Peak Titer Log10TCID50/ml (37˚C)

Virus
BR08

MDCK (4.61) > Trachea (3.16) > NT (3.04) > Lung (2.85)

FL06

MDCK (5.24) > NT (3.7) > Trachea (3.6) > Lung (3.46)

HK17

NT (4.65) > Lung (4.49) > MDCK (4.45) > Trachea (3.3)

UT14

MDCK (5.44) > NT (4.3) > Trachea (3.38) > Lung (3.35)

Table 4.2 shows the peak viral titers (log10TCID50/ml) B/Brisbane/60/2008 (BR08),
B/Florida/04/06 (FL06), B/Hong Kong/286/2017 (HK17) and B/Utah/09/2014 (UT14)
grew to in nasal turbinate(NT), trachea (T), lung (L) and MDCK cells in decreasing
order of titers at 33˚C and 37˚C at 0.1 multiplicity of infection.

Temperature & MOI

NT

Trachea

Lung

MDCK

33˚C and 0.01 MOI

HK17 (4.36) UT14 (4.49)

HK17 (4.33) BR08 (5.36)

33˚C and 0.1 MOI

HK17 (4.31) FL06 (5.38)

HK17 (4.47) FL06 (5.57)

37˚C and 0.01 MOI

HK17 (3.58) FL06 (3.53)

HK17 (3.51) BR08 (5.32)

37˚C and 0.1 MOI

HK17 (4.65) FL06 (3.66)

HK17 (4.49) UT14 (5.44)

Table 4.3 shows the peak titers B/Brisbane/60/2008 (BR08), B/Florida/04/06 (FL06),
B/Hong Kong/286/2017 (HK17) and B/Utah/09/2014 (UT14) replicated to in swine
primary nasal turbinate (NT), trachea (T), lung (L) and MDCK cells at different
temperatures and MOIs

Swine primary respiratory epithelial cells derived from nasal turbinate, trachea and lungs
were infected with four IBV strains (Figure 4.1). The viruses belonging to the Victoria
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lineage were B/Brisbane/60/2008 (BR08) and B/Hong Kong/286/2017 (HK17);
Yamagata lineage were B/Florida/04/2006 (FL06) and B/Utah/09/2014 (UT14).
Replication kinetics in the primary cells were compared to MDCK cells. The TCID50
titers of the stock viruses were 3.16x106 TCID50/ml and 2.67x106 TCID50/ml for BR08,
2.37x106 TCID50/ml for FL04; 1.58x106 TCID50/ml and 1.9x106 TCID50/ml for HK17;
3x107 TCID50/ml for UT14.
Infection experiments were done at 0.01 MOI and 0.1 MOI. TPCK trypsin was used at a
concentration of 0.01 µg/ml (0.001%) on the primary epithelial cells to cause minimum
cell toxicity, whereas 1µg/ml (0.1%) was used for infecting MDCK cells.
4.3.1 Replication Kinetics in Nasal Turbinate Cells at 0.01 MOI
All four viruses replicated productively in nasal turbinate cells at 33˚C (Figure 4.2a).
FL06 reached a peak of 3.37 logs by 48 hours post infection (hpi), whereas BR08, HK17
and UT14 reached their maximum titers of 3.35 logs, 4.36 logs and 3.29 logs by 72 hpi.
All four viruses followed a similar trend to MDCK cells at 33˚C; reaching their peak
titers at the same time points in nasal turbinate cells as in MDCK cells.
Replication of the four IBVs at 37˚C was less productive than the replication at 33˚C.
While HK17 grew best to a titer of 3.58 logs, FL06 and UT14 grew to titers 2.56 logs and
2.44 logs respectively. Interestingly, BR08 had a low titer of 1.77 logs by 72 hpi at 37˚C.
MDCK cells supported all the viruses better than nasal turbinate cells at 37˚C.
4.3.2 Replication Kinetics in Nasal Turbinate Cells at 0.1 MOI
By 24h post infection, BR08 replicated to a titer of 3.84 logs at 33˚C and 3.04 logs at
37˚C, showing no significant difference in titers between the two temperatures. Similarly,
HK17 grew to titers of 4.31 logs at 33˚C and 4.65 logs at 37˚C by 72 hpi while UT14
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grew to 3.99 logs at 33˚C and 4.34 logs at 37˚C. Contrastingly, FL06 grew better at 33˚C,
reaching a peak titer of 4.25 logs at 33˚C (Figure 4.2b).
4.3.3 Replication Kinetics in Trachea Cells at 0.01 MOI
Trachea cells supported the replication of the four IBVs when infected at 33˚C (Figure
4.3a). At this temperature, BR08 and HK17 had no titer by 24 hpi, whereas FL06 and
UT14 began replicating by 24 hours post-infection. BR08, HK17 and UT14 showed
higher peak viral titers at 33˚C when compared to 37˚C. The titers obtained were 3.43
logs for BR08, 4.36 logs for HK17 and 4.49 logs for UT14. FL06 replicated equally well
at both temperatures reaching 3.53 logs at 37˚C. Interestingly, all the viruses had no titer
by 120 hpi in the trachea cells.
4.3.4 Replication Kinetics in Trachea Cells at 0.1 MOI
FL06 replicated the best in trachea cells reaching a titer of 5.38 logs by 48 hours postinfection. BR08 and UT14 followed similar patterns of replication, reaching peak titers of
4.14 logs and 4.34 logs respectively by 72 hpi. HK17 exhibited the lowest titers at 33˚C,
reaching 3.42 logs by 96 hpi. While HK17 grew equally well at 33˚C and 37˚C, BR08,
FL06 and UT14 were supported better by trachea cells at 33˚C. The pattern of replication
varied as well, with BR08, FL06 and HK17 reaching peak titers earlier at 37˚C. By 120
hpi, BR08 and FL06 were not replicating (Figure 4.3b).

4.3.5 Replication Kinetics in Lung Cells at 0.01 MOI
Lung cells support the replication of all four viruses, with HK17 growing most efficiently
to a peak titer of 4.33 logs at 72 hpi (Figure 4.4a). BR08 and UT14 replicated to higher
titers at 33˚C, reaching peak titers of 2.43 logs at 48 hpi and 3.40 logs at 48 hpi
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respectively. FL06 replicated more efficiently at 37˚C with a peak titer of 3.38 logs by 24
hpi. This was similar to the pattern of replication in MDCK cells at 0.01 MOI, where
FL06 grew better at 37˚C, reaching a peak titer of 4.36 logs. By 120 hpi only FL06 had a
titer.
4.3.6 Replication Kinetics in Lung Cells at 0.1 MOI
BR08, FL06 and UT14 reached peak titers of 4.46 logs at 48 hpi, 4.25 logs at 72 hpi and
4.34 logs at 48 hpi respectively in the 33˚C experiment (Figure 4.4b). These three viruses
replicated less efficiently in at 37˚C, reaching peak titers of 2.85 logs at 72 hpi (BR08),
3.46 logs at 24 hpi (FL06) and 3.35 logs at 48 hpi (UT14). HK17 displayed similar
growth curves and peak viral titers growing of 4.45 logs at 48 hpi at both temperatures.
4.3.7 Replication Kinetics of MDCK Cells at 0.01 MOI
All four viruses reached high titers in MDCK cells at 33˚C and 37˚C (Figure 4.5a). No
significant differences in titers were seen between the two temperatures for BR08, HK17,
and UT14. BR08 grew the best at 33˚C, reaching 5.36 logs, whereas HK17 and UT14
grew to peak titers of 4.51 logs and 4.34 logs respectively. BR08 grew to a high titer of
5.32 logs by 72 hpi at 37˚C, while HK17 and UT14 replicated to titers of 4.42 logs at 48
hpi and 4.40 logs at 72 hpi respectively. FL06 replicated slightly better at 37˚C reaching a
titer of 4.36 logs by 48 hpi, whereas it only grew to 3.94 logs at 48 hpi in the 33˚C
experiment.

4.3.8 Replication Kinetics of MDCK Cell at 0.1 MOI
When MDCK cells were infected with one of the four viruses at 0.1 MOI, the titers
obtained at 37˚C were lesser than or equal to the titers obtained at 33˚C. BR08 showed a
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significant difference in titers between the two temperatures, growing to 5.35 logs by 48
hpi at 33˚C, whereas at 37˚C it grew to a peak titer of 4.61 logs by 48 hpi. At 33˚C FL06,
HK17 and UT14 grew to titers of 5.57 logs at 48 hpi, 4.45 logs at 48 hpi and 5.40 logs at
48 hpi respectively. Similar peak titers of 5.24 logs at 24 hpi, 4.45 logs at 48 hpi and 5.44
logs at 48 hpi were seen for these three viruses at 37˚C (Figure 4.5b).
BR08 showed productive replication at 33˚C in all three primary cells and MDCK cells.
In the 33˚C experiments, the highest titers were seen in MDCK cells (5.3 logs) followed
by lung cells (4.46 logs). Higher titers were observed when all cells were infected with
BR08 at 0.1 MOI compared to 0.01 MOI (Table 4.1 and 4.2). In the 37˚C experiments,
replication of BR08 was restricted to less than 2 logs in the primary cells at 0.01 MOI.
Interestingly, MDCK cells yielded a titer of 5.3 logs when infected with BR08 at 37˚C
and 0.01 MOI.
FL06 showed the highest titer of 5.57 logs in MDCK cells when infected at 33˚C and 0.1
MOI. Unlike BR08, in the 0.01 MOI experiments, comparable titers were seen at both
temperatures. Amongst the primary cells, the highest titer was observed in trachea cells
(5.38 logs) at 33˚C and 0.1 MOI. It was seen that in the 33˚C experiments, peak titers of
FL06 were reached at 48h in all cell types except lung cells at 0.1 MOI which showed the
peak titer at 72h.
HK17 showed productive replication at both temperatures and MOIs. No significant
differences were seen in titers between 33˚C and 37˚C in the 0.1 MOI experiment,
whereas at 0.01 MOI, the titers at 33˚C were a log higher than titers at 37˚C in the
primary cells. The highest titer for HK17 (4.65 logs) was seen in nasal turbinate cells at
37˚C in the 0.1 MOI experiment (Table 4.3).
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UT14 grew best in MDCK cells at 0.1 MOI and 37˚C, reaching a peak titer of 5.44 logs
by 48 hpi. At 0.01 MOI, nasal turbinate and trachea cells exhibited a higher titer at 33˚C
compared to 37˚C. No significant differences in titers were seen in lung and MDCK cells
between both temperatures. At 0.1 MOI, UT14 grew best in MDCK cells reaching a peak
titer of 5.44 logs, followed by nasal turbinate cells in which it replicated to 4.34 logs at 72
hpi.

4.4 Discussion
This study looked at the utility of a swine isogenous cell culture system in studying the
replication kinetics of influenza B virus (IBV) at ambient temperatures that correspond to
the upper and lower respiratory tract of swine. The nasal turbinate trachea and lung swine
primary respiratory epithelial cells represent the upper, middle and lower respiratory tract
of swine, respectively. The replication of B/Brisbane/60/2008 (BR08) and B/Hong
Kong/286/2017 (HK17) belonging to the Victoria lineage, and B/Florida/04/06 (FL06)
and B/Utah/09/2014 (UT14) belonging to the Yamagata lineage was studied at 33˚C and
37˚C. The three primary cells, and MDCK cells which were used as a positive control,
were infected with the four strains of IBV at 0.01 and 0.1 multiplicities of infection.
Though humans are accepted to be the only reservoir for IBV, there is evidence of IBV
infections in non-human species. Antibodies to IBV detected in swine in the 1960s and in
2015 indicate the exposure of swine to this virus (Ran et al., 2015; Takatsy & Farkas,
1969). Furthermore, animal studies conducted have shown that IBV is capable of
replicating in swine (Takatsy & Farkas, 1969). The natural infection of IBV in pigs in
Taiwan, although sporadic, is a public health concern as it can lead to human-swine-
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human transmission in the future (Tsai & Tsai, 2019). Reassortment of IBV with other
influenza viruses in pigs can also create the potential for new zoonotic viruses.
This study demonstrates that IBV is capable of replicating in the in vitro model of the
swine respiratory tract. Our previous study showed that BR08 and FL06 replicated in the
nasal turbinate, trachea and lung primary epithelial cells when infected with 0.1 MOI at
33˚C and 37˚C (Sreenivasan et al., 2019). Here we show that appreciable viral titers can
be observed at a lower multiplicity of infection (0.01 MOI) as well. In addition,
successful replication of contemporary strains HK17 and UT14 is observed in these
primary cells.
IBV replicated in a temperature dependent manner in all three primary cells. Peak titers at
33˚C were greater than or equal to titers at 37˚C for most of the experiments. Exceptions
include HK17 which when infected at 0.1 MOI in the nasal turbinate cells grew to 0.3
logs higher at 37˚C. Infection of MDCK cells did not result in significant differences in
titer between the two temperatures.
The growth of BR08, FL06 and UT17 was supported best by MDCK cells, which lack
the anti-influenza activity of canine Mx protein (Frensing et al., 2011). Interestingly,
HK17 (Victoria lineage) grew to the highest titers in nasal turbinate and lung cells. This
is in line with the swine seroprevalence study done in 2015, which showed that higher HI
antibody titers were seen in viruses belonging to the Victoria lineage when compared to
the Yamagata lineage (Ran et al., 2015). The growth of BR08, FL06 and UT14 was suboptimal in the primary cells, although close to that in MDCK cells at certain conditions.
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Notably, lineage-specific differences in replication could not be observed in this study.
Further investigation into the molecular basis for the differences in replication between
the older BR08 and contemporary HK17 will shed more light on the role of swine in the
pathogenesis of IBV.
The submerged monolayer of swine primary cells used in this study does not accurately
mimic the three-dimensional architecture of the swine respiratory tract. Experiments
performed in 3D cell culture systems or air liquid interface systems would provide
additional information at a cellular level when studying the tropism and infectivity of
influenza viruses (Allen C. Bateman, Karasin, & Olsen, 2013; Elderfield et al., 2015; H.
Y. Wang et al., 2018).
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